

What does the PANSS mean?

Schizophrenia Research

79, 231-238

DOI: [10.1016/j.schres.2005.04.008](https://doi.org/10.1016/j.schres.2005.04.008)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Beta-blocker supplementation of standard drug treatment for schizophrenia. The Cochrane Library, 2001, , CD000234.	1.5	6
2	Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness. The Cochrane Library, 2001, , CD001360.	1.5	48
3	Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. The Cochrane Library, 2003, , CD000208.	1.5	26
4	Benperidol for schizophrenia. The Cochrane Library, 2005, , CD003083.	1.5	4
5	Linking the PANSS, BPRS, and CGI: Clinical Implications. Neuropsychopharmacology, 2006, 31, 2318-2325.	2.8	257
6	A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophrenia Research, 2006, 84, 77-89.	1.1	85
7	Lamotrigine for schizophrenia. The Cochrane Library, 2006, , CD005962.	1.5	41
8	Family intervention for schizophrenia. , 2006, , CD000088.		378
9	Utilization of Long-Acting Antipsychotic Medication in Patient Care. CNS Spectrums, 2006, 11, 1-8.	0.7	29
10	Educational games for mental health professionals. The Cochrane Library, 2006, , CD001471.	1.5	22
11	Optimizing Early Prediction for Antipsychotic Response in Schizophrenia. Journal of Clinical Psychopharmacology, 2006, 26, 554-559.	0.7	54
12	To What Extent Do the PANSS and CGI-S Overlap?. Journal of Clinical Psychopharmacology, 2006, 26, 303-307.	0.7	38
13	Eleven-year clinical outcome of schizophrenia in Bali. Acta Psychiatrica Scandinavica, 2006, 114, 68-68.	2.2	0
17	Intramuscular haloperidol and olanzapine begin to reduce psychosis within 24 hours. Evidence-Based Mental Health, 2006, 9, 9-9.	2.2	0
18	Deficient relational binding processes in adolescents with psychosis: Evidence from impaired memory for source and temporal context. Cognitive Neuropsychiatry, 2007, 12, 511-536.	0.7	23
19	Unanswered Questions in Schizophrenia Clinical Trials. Schizophrenia Bulletin, 2007, 34, 302-309.	2.3	24
20	Defining "Response"™ in Antipsychotic Drug Trials: Recommendations for the Use of Scale-Derived Cutoffs. Neuropsychopharmacology, 2007, 32, 1903-1910.	2.8	171
21	Methodological Issues in Current Antipsychotic Drug Trials. Schizophrenia Bulletin, 2007, 34, 275-285.	2.3	76

#	ARTICLE	IF	CITATIONS
29	Symptom rating scales and outcome in schizophrenia. British Journal of Psychiatry, 2007, 191, s7-s14.	1.7	114
30	Clozapine and Amisulpride in Refractory Schizophrenia and Alcohol Dependence. Journal of Clinical Psychopharmacology, 2007, 27, 514-516.	0.7	10
31	High-Dose Ziprasidone in Treatment-Resistant Schizophrenia and Affective Spectrum Disorders. Journal of Clinical Psychopharmacology, 2007, 27, 513-514.	0.7	9
32	Intravenous Valproate Treatment of Uncontrollable Aggression. Journal of Clinical Psychopharmacology, 2007, 27, 529-531.	0.7	0
33	Neuroreceptor Gene Polymorphisms and Olanzapine Depressive Symptom Response in Schizophrenia. Journal of Clinical Psychopharmacology, 2007, 27, 520-523.	0.7	5
34	Comments on "Neurological Soft Signs in Schizophrenic Patients Treated With Conventional and Atypical Antipsychotics". Journal of Clinical Psychopharmacology, 2007, 27, 528.	0.7	0
35	Aripiprazole for Relapse Prevention and Craving in Alcohol-Dependent Subjects. Journal of Clinical Psychopharmacology, 2007, 27, 519-520.	0.7	34
36	Significant Elevations of Prolactin Levels in Patients Who Shifted From Conventional Depot Antipsychotics to Long-Acting Risperidone. Journal of Clinical Psychopharmacology, 2007, 27, 523-524.	0.7	6
37	Increase in Plasma Concentration of Amisulpride After Addition of Concomitant Lithium. Journal of Clinical Psychopharmacology, 2007, 27, 546-549.	0.7	13
39	Resolution of Tardive Dyskinesia After Addition of Aripiprazole to Haloperidol Depot. Journal of Clinical Psychopharmacology, 2007, 27, 525-526.	0.7	14
40	Pregabalin in Patients With Antidepressant Treatment-Resistant Somatoform Disorders. Journal of Clinical Psychopharmacology, 2007, 27, 537-539.	0.7	15
41	Are the Effects of Rater Training Sustainable?. Journal of Clinical Psychopharmacology, 2007, 27, 534-535.	0.7	11
42	Perceptual Disturbances Associated With Low-Dose Bupropion Sustained-Release Treatment. Journal of Clinical Psychopharmacology, 2007, 27, 543-544.	0.7	4
43	Long-Term Lithium Treatment and Survival From External Causes Including Suicide. Journal of Clinical Psychopharmacology, 2007, 27, 544-546.	0.7	9
44	GABAergic Medications for Treating Alcohol Dependence. Journal of Clinical Psychopharmacology, 2007, 27, 539-540.	0.7	1
45	Comments on "Why Do Clinical Trials Fail? The Problem of Measurement Error in Clinical Trials. Journal of Clinical Psychopharmacology, 2007, 27, 535-537.	0.7	3
46	Unfavorable Smell With Citalopram?. Journal of Clinical Psychopharmacology, 2007, 27, 528-529.	0.7	10
47	Aripiprazole Improves Metabolic Adversity in Olanzapine-Treated Schizophrenic Patients. Journal of Clinical Psychopharmacology, 2007, 27, 516-517.	0.7	11

#	ARTICLE	IF	CITATIONS
48	Loxapine for schizophrenia. The Cochrane Library, 2015, 2015, CD001943.	1.5	43
49	Evidence-Based Guidelines for Interpretation of the Hamilton Rating Scale for Depression. Journal of Clinical Psychopharmacology, 2007, 27, 531-534.	0.7	80
50	Acute Urinary Retention Associated With Selective Serotonin Reuptake Inhibitors and Ziprasidone. Journal of Clinical Psychopharmacology, 2007, 27, 517-519.	0.7	10
51	Reply to Dr Caputo and Colleagues Regarding "GABAergic Medications for Treating Alcohol Dependence". Journal of Clinical Psychopharmacology, 2007, 27, 540-542.	0.7	0
52	Resolution of Haloperidol-Induced Hyperprolactinemia With Aripiprazole. Journal of Clinical Psychopharmacology, 2007, 27, 524-525.	0.7	13
53	Quetiapine as Treatment for Delirium During Weaning From Ventilation. Journal of Clinical Psychopharmacology, 2007, 27, 526-528.	0.7	6
54	Megadose Clonazepam Dependence. Journal of Clinical Psychopharmacology, 2007, 27, 542-543.	0.7	13
55	Chlorpromazine versus placebo for schizophrenia. , 2007, , CD000284.		42
56	Conceptual and Methodological Issues??in the Design of Clinical Trials??of Antipsychotics for the Treatment??of Schizophrenia. CNS Drugs, 2007, 21, 699-714.	2.7	28
57	Testosterone for schizophrenia. The Cochrane Library, 2007, , CD006197.	1.5	14
58	Analysis Linking UCLA PCI With Expanded Prostate Cancer Index Composite: An Evaluation of Health Related Quality of Life in Japanese Men With Localized Prostate Cancer. Journal of Urology, 2007, 178, 473-477.	0.2	24
59	The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophrenia Research, 2007, 94, 99-106.	1.1	46
60	Questioning an Axiom: Better Prognosis for Schizophrenia in the Developing World?. Schizophrenia Bulletin, 2007, 34, 229-244.	2.3	216
61	Measurement of long-term outcomes in observational and randomised controlled trials. British Journal of Psychiatry, 2007, 191, s78-s84.	1.7	25
62	Open general medical wards versus specialist psychiatric units for acute psychoses. The Cochrane Library, 2007, , CD003290.	1.5	12
67	Statistical validation of the criteria for symptom remission in schizophrenia: Preliminary findings. BMC Psychiatry, 2007, 7, 35.	1.1	66
68	Assessment of remission in schizophrenia with the CGI and CGI-SCH scales. Acta Psychiatrica Scandinavica, 2007, 115, 163-164.	2.2	23
70	On the concept of remission in schizophrenia. Psychopharmacology, 2007, 194, 453-461.	1.5	46

#	ARTICLE	IF	CITATIONS
71	Routine evaluation in first episode psychosis services: feasibility and results from the MiData project. Social Psychiatry and Psychiatric Epidemiology, 2008, 43, 960-967.	1.6	49
72	Design paper: The CapOpus trial: A randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis. Trials, 2008, 9, 42.	0.7	13
73	Pituitary volume in unaffected relatives of patients with schizophrenia and bipolar disorder. Psychoneuroendocrinology, 2008, 33, 1004-1012.	1.3	65
74	Extrapolation between measures of symptom severity and change: An examination of the PANSS and CGI. Schizophrenia Research, 2008, 98, 318-322.	1.1	103
75	World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophrenia Research, 2008, 100, 20-38.	1.1	240
76	Validation of a Clinical Global Impression Scale for Aggression (CGI-A) in a sample of 558 psychiatric patients. Schizophrenia Research, 2008, 100, 342-348.	1.1	39
77	Novel rating scales for schizophrenia – Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). Schizophrenia Research, 2008, 106, 328-336.	1.1	27
78	Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Research, 2008, 161, 213-224.	1.7	186
79	Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia. Clinical Therapeutics, 2008, 30, 231-248.	1.1	31
80	Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia –†. Schizophrenia Research, 2008, 102, 230-240.	1.1	141
81	Oral paliperidone for schizophrenia. The Cochrane Library, 2008, , CD006369.	1.5	22
82	Cannabis and schizophrenia. , 2008, , CD004837.		20
83	Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia. Schizophrenia Bulletin, 2008, 34, 1163-1171.	2.3	101
84	Executive Attention in Schizophrenic Males and the Impact of COMT Val108/158Met Genotype on Performance on the Attention Network Test. Schizophrenia Bulletin, 2008, 34, 1231-1239.	2.3	45
85	Aripiprazole versus typicals for schizophrenia. , 2008, , CD006617.		10
86	Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnesses. The Cochrane Library, 2008, , CD006570.	1.5	26
87	Life skills programmes for chronic mental illnesses. , 2008, , CD000381.		26
88	New-Onset Schizophrenia: Pharmacologic Treatment. Focus (American Psychiatric Publishing), 2008, 6, 167-171.	0.4	0

#	ARTICLE	IF	CITATIONS
89	Aripiprazole versus typical antipsychotic drugs for schizophrenia. The Cochrane Library, 2008, , CD006617.	1.5	30
90	Rehabilitation programmes for schizophrenia. The Cochrane Library, 0, , .	1.5	0
91	Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. International Clinical Psychopharmacology, 2008, 23, 343-356.	0.9	75
92	Ranking of Outcome Domains for Use in Real-Time Outcomes Feedback Laboratory by Patients With Schizophrenia. Journal of Nervous and Mental Disease, 2008, 196, 336-339.	0.5	4
93	A Fine-Grained Analysis of the Jumping to Conclusions Bias in Schizophrenia: Data-Gathering, Response Confidence, and Information Integration. SSRN Electronic Journal, 0, , .	0.4	8
95	Olanzapine depot for schizophrenia. The Cochrane Library, 0, , .	1.5	1
96	Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Schizophrenia Bulletin, 2009, 35, 443-457.	2.3	360
97	Increased Plasma Brain-Derived Neurotrophic Factor, Not Nerve Growth Factor-Beta, in Schizophrenia Patients with Better Response to Risperidone Treatment. Neuropsychobiology, 2009, 59, 51-58.	0.9	61
98	Chlorpromazine Dose for People With Schizophrenia. Schizophrenia Bulletin, 2009, 35, 491-492.	2.3	26
99	Effects of phonological and semantic cuing on encoding and retrieval processes in adolescent psychosis. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 533-544.	0.8	6
100	The effect of clozapine on regional cerebral blood flow and brain metabolite ratios in schizophrenia: Relationship with treatment response. Psychiatry Research - Neuroimaging, 2009, 174, 121-129.	0.9	57
101	Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Human Psychopharmacology, 2009, 24, 628-638.	0.7	51
102	Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. Depression and Anxiety, 2009, 26, 922-929.	2.0	120
103	Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials. BMC Psychiatry, 2009, 9, 13.	1.1	7
104	Patient health outcomes in psychiatric mental health nursing. Journal of Psychiatric and Mental Health Nursing, 2009, 16, 32-45.	1.2	12
105	Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatrica Scandinavica, 2009, 119, 7-14.	2.2	173
106	The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 214-219.	2.5	44
107	Expression of neuronal calcium sensor-1 (NCS-1) is decreased in leukocytes of schizophrenia and bipolar disorder patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 229-234.	2.5	31

#	ARTICLE	IF	CITATIONS
108	Evaluating integrated MI and CBT for people with psychosis and substance misuse: Recruitment, retention and sample characteristics of the MIDAS trial. Addictive Behaviors, 2009, 34, 859-866.	1.7	42
109	Optimal thresholds of early response to atypical antipsychotics: Application of signal detection methods. Schizophrenia Research, 2009, 113, 34-40.	1.1	25
110	Day hospital versus outpatient care for people with schizophrenia. The Cochrane Library, 2009, , CD003240.	1.5	29
111	Risperidone dose for schizophrenia. The Cochrane Library, 2009, , CD007474.	1.5	24
112	The effectiveness of technology-based patient education on self-reported deprivation of liberty among people with severe mental illness: A randomized controlled trial. Nordic Journal of Psychiatry, 2009, 63, 383-389.	0.7	19
113	Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Current Medical Research and Opinion, 2009, 25, 325-338.	0.9	107
114	Insights from the examination of verbal and spatial memory errors in relation to clinical symptoms of patients with recent-onset schizophrenia. Cognitive Neuropsychiatry, 2009, 14, 542-558.	0.7	2
115	Comparative utility of aripiprazole and haloperidol in schizophrenia. Applied Health Economics and Health Policy, 2009, 7, 109-119.	1.0	15
116	Clozapine versus typical neuroleptic medication for schizophrenia. The Cochrane Library, 2009, , CD000059.	1.5	155
118	Using Patient-Reported Outcomes in Schizophrenia: The Scottish Schizophrenia Outcomes Study. Psychiatric Services, 2009, 60, 240-245.	1.1	40
119	Monetary incentives for schizophrenia. The Cochrane Library, 2009, , CD007626.	1.5	2
120	Sulpiride versus other antipsychotics for schizophrenia. The Cochrane Library, 0, , .	1.5	5
121	Cognitive behaviour therapy versus standard care for schizophrenia. The Cochrane Library, 2009, , .	1.5	7
124	Sulpiride versus placebo for schizophrenia. , 2009, , CD007811.		15
125	Cognitive behaviour therapy versus specific pharmacological treatments for schizophrenia. The Cochrane Library, 2009, , .	1.5	6
126	Advance treatment directives for people with severe mental illness. The Cochrane Library, 2009, , CD005963.	1.5	62
127	Ziprasidone versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2009, , CD006627.	1.5	45
128	Aripiprazole versus other atypical antipsychotics for schizophrenia. , 2009, , CD006569.		57

#	ARTICLE	IF	CITATIONS
129	Sertindole versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2009, , CD006752.	1.5	13
132	Concordance Between Measures of Functioning, Symptoms, and Change. Journal of Clinical Psychopharmacology, 2010, 30, 478-480.	0.7	19
133	Does Clinical Judgment of Baseline Severity and Changes in Psychopathology Depend on the Patient Population?. Journal of Clinical Psychopharmacology, 2010, 30, 726-731.	0.7	24
134	Intensive case management for severe mental illness. , 2010, , CD007906.		271
135	A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. International Clinical Psychopharmacology, 2010, 25, 1-6.	0.9	46
136	Quetiapine versus other atypical antipsychotics for schizophrenia. , 2010, , CD006625.		122
138	Zotepine versus other atypical antipsychotics for schizophrenia. , 2010, , CD006628.		10
139	Physical health care monitoring for people with serious mental illness. , 2010, , CD008298.		22
140	Disease Management: Multidimensional Approaches to Incomplete Recovery in Psychosis. Advances in Biological Psychiatry, 2010, , 87-113.	0.2	6
141	Zotepine versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2010, , CD006628.	1.5	7
142	Sulpiride augmentation for schizophrenia. The Cochrane Library, 2010, , CD008125.	1.5	25
143	The nature of attentional dysfunctions in adolescents hospitalized for a first episode of psychosis. Journal of Neuropsychology, 2010, 4, 47-70.	0.6	6
144	Evidence of the effectiveness of a specialist vocational intervention following first episode psychosis: a naturalistic prospective cohort study. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 1-8.	1.6	48
146	Antipsychotics for people with persistent negative symptoms of schizophrenia. The Cochrane Library, 2010, , .	1.5	1
148	Asenapine versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2010, , .	1.5	2
149	Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Current Medical Research and Opinion, 2010, 26, 2403-2410.	0.9	44
150	Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia. Neuropsychopharmacology, 2010, 35, 581-590.	2.8	165
151	Evidence for gamma inhibition deficits in the dorsolateral prefrontal cortex of patients with schizophrenia. Brain, 2010, 133, 1505-1514.	3.7	137



#	ARTICLE	IF	CITATIONS
152	Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 635-647.	1.0	138
153	A pilot study to determine whether machine learning methodologies using pre-treatment electroencephalography can predict the symptomatic response to clozapine therapy. <i>Clinical Neurophysiology</i> , 2010, 121, 1998-2006.	0.7	77
154	INTERIM ANALYSIS OF THE CAPOPUS TRIAL: A RANDOMIZED, PARALLEL-GROUP, OBSERVER-BLINDED CLINICAL TRIAL OF SPECIALIZED ADDICTION TREATMENT VERSUS TREATMENT AS USUAL FOR YOUNG PATIENTS WITH CANNABIS ABUSE AND PSYCHOSIS. <i>Schizophrenia Research</i> , 2010, 117, 190.	1.1	4
155	Video-based quantification of body movement during social interaction indicates the severity of negative symptoms in patients with schizophrenia. <i>Schizophrenia Research</i> , 2010, 121, 90-100.	1.1	77
156	Safety and proof of principle study of cerebellar vermal theta burst stimulation in refractory schizophrenia. <i>Schizophrenia Research</i> , 2010, 124, 91-100.	1.1	154
157	Amisulpride versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD006624.	1.5	26
158	Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia. <i>Psychiatry Research</i> , 2010, 179, 12-18.	1.7	15
159	Management of hallucinations and psychosis in Parkinson's disease. <i>American Journal of Geriatric Pharmacotherapy</i> , 2010, 8, 316-330.	3.0	44
160	Family intervention for schizophrenia. <i>The Cochrane Library</i> , 0, , .	1.5	218
161	Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial. <i>Neuropsychopharmacology</i> , 2010, 35, 2367-2377.	2.8	108
162	Clozapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD006633.	1.5	130
163	Olanzapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD006654.	1.5	120
164	Psychoeducation for schizophrenia. <i>The Cochrane Library</i> , 2011, , CD002831.	1.5	279
165	Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2011, 25, 567-620.	2.0	332
167	Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. <i>The Cochrane Library</i> , 2011, , CD000203.	1.5	27
168	Day hospital versus admission for acute psychiatric disorders. <i>The Cochrane Library</i> , 2011, , CD004026.	1.5	73
169	Evidence-based pharmacotherapy of schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 269-284.	1.0	87
170	Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. <i>Schizophrenia Research</i> , 2011, 126, 212-219.	1.1	34

#	ARTICLE	IF	CITATIONS
171	The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophrenia Research, 2011, 128, 166-170.	1.1	73
172	Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Schizophrenia Research, 2011, 128, 127-135.	1.1	30
173	Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophrenia Research, 2011, 130, 11-19.	1.1	34
174	Prefrontal lobe dysfunction predicts treatment response in medication-naïve first-episode schizophrenia. Schizophrenia Research, 2011, 129, 156-162.	1.1	59
176	Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders. Clinical Pharmacokinetics, 2011, 50, 429-450.	1.6	34
177	Aripiprazole versus placebo for schizophrenia. The Cochrane Library, 2011, , CD006622.	1.5	26
178	Early intervention for psychosis. The Cochrane Library, 2011, , CD004718.	1.5	235
179	Risperidone versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2011, , CD006626.	1.5	69
180	Celecoxib for schizophrenia. The Cochrane Library, 2011, , .	1.5	3
182	No association between the Catechol-O-Methyltransferase (COMT) val158met polymorphism and cognitive improvement following cognitive remediation therapy (CRT) in schizophrenia. Neuroscience Letters, 2011, 496, 65-69.	1.0	40
183	Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Research, 2011, 187, 42-48.	1.7	63
184	Treatment resistant schizophrenia and response to antipsychotics: A review. Schizophrenia Research, 2011, 133, 54-62.	1.1	99
185	Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia. European Psychiatry, 2011, 26, 313-319.	0.1	14
188	Enhanced crisis planning for serious mental illness. The Cochrane Library, 2011, , .	1.5	0
191	Haloperidol Versus Second-Generation Antipsychotics in the Long-Term Treatment of Schizophrenia. Journal of Clinical Psychopharmacology, 2011, 31, 661-663.	0.7	7
192	Antipsychotic combinations for schizophrenia. , 2011, , .		7
194	Antipsychotic medication for early episode schizophrenia. The Cochrane Library, 2017, 2017, CD006374.	1.5	19
195	Oral health advice for people with serious mental illness. , 2011, , CD008802.		25

#	ARTICLE	IF	CITATIONS
196	Music therapy for people with schizophrenia and schizophrenia-like disorders. , 2011, , CD004025.		124
197	Compulsory community and involuntary outpatient treatment for people with severe mental disorders. , 2011, , CD004408.		61
198	Calcium channel blockers for neuroleptic-induced tardive dyskinesia. The Cochrane Library, 2011, , CD000206.	1.5	26
199	Bromperidol decanoate (depot) for schizophrenia. , 2011, , CD001719.		0
201	Risperidone for psychosis induced aggression or agitation. The Cochrane Library, 0, , .	1.5	13
202	Mood stabilisers for schizoaffective disorder. The Cochrane Library, 2011, , .	1.5	0
203	Clinical relevance of findings in trials of antipsychotics: systematic review. British Journal of Psychiatry, 2011, 198, 341-345.	1.7	74
204	Remission in schizophrenia: A community-based 6-year follow-up study in Bali. Psychiatry and Clinical Neurosciences, 2011, 65, 476-482.	1.0	22
205	Quantifying Clinical Relevance in the Treatment of Schizophrenia. Clinical Therapeutics, 2011, 33, B16-B39.	1.1	94
207	Effect of methamphetamine dependence on inhibitory deficits in a novel human open-field paradigm. Psychopharmacology, 2011, 215, 697-707.	1.5	31
208	Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health and Quality of Life Outcomes, 2011, 9, 18.	1.0	99
209	Using A Pharmacy-Based Intervention To Improve Antipsychotic Adherence Among Patients With Serious Mental Illness. Schizophrenia Bulletin, 2011, 37, 727-736.	2.3	73
210	Algılanan Aile Yeterliliği - İlaç Etkinliği'nin Tanımlanması ve Güvenilirlik ve Geçerliliği'nin Değerlendirilmesi. Nöropsikiyatri Arsivi, 2011, 48, 1-1.	0.7	5
211	A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes. American Journal of Psychiatry, 2011, 168, 472-485.	4.0	1,437
212	Oral Health Advice for People With Serious Mental Illness. Schizophrenia Bulletin, 2011, 37, 464-465.	2.3	18
213	Neurocognitive prediction of illness knowledge after psychoeducation in schizophrenia: results from the Munich COGPIP study. Psychological Medicine, 2011, 41, 533-544.	2.7	22
214	Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. The Cochrane Library, 2011, , CD000524.	1.5	14
215	Social skills programmes for schizophrenia. , 2011, , .		4

#	ARTICLE	IF	CITATIONS
216	Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. <i>Translational Psychiatry</i> , 2011, 1, e36-e36.	2.4	102
217	Vitamin E for neuroleptic-induced tardive dyskinesia. <i>The Cochrane Library</i> , 2011, , CD000209.	1.5	63
218	Tinnitus Handicap Inventory for Evaluating Treatment Effects. <i>Otolaryngology - Head and Neck Surgery</i> , 2011, 145, 282-287.	1.1	164
219	Prevalence of Celiac Disease and Gluten Sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness Study Population. <i>Schizophrenia Bulletin</i> , 2011, 37, 94-100.	2.3	135
220	Real-Time Electronic Ambulatory Monitoring of Substance Use and Symptom Expression in Schizophrenia. <i>American Journal of Psychiatry</i> , 2011, 168, 202-209.	4.0	101
221	Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial. <i>Neuropsychopharmacology</i> , 2012, 37, 660-668.	2.8	102
222	Trajectories of Agouti-Related Protein and Leptin Levels During Antipsychotic-Associated Weight Gain in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 767-772.	0.7	16
223	Optimizing the Early Prediction Model for Symptomatic Remission With Short-Term Treatment for Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 773-777.	0.7	3
224	Benzodiazepines for schizophrenia. <i>The Cochrane Library</i> , 2012, 11, CD006391.	1.5	66
225	Parallel but not equivalent: Challenges and solutions for repeated assessment of cognition over time. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 758-772.	0.8	37
226	Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia. <i>The Cochrane Library</i> , 2012, , CD008712.	1.5	94
227	Domains and Determinants of Quality of Life in Schizophrenia and Systemic Lupus Erythematosus. <i>Indian Journal of Psychological Medicine</i> , 2012, 34, 49-55.	0.6	5
228	Antipsychotic agents: efficacy and safety in schizophrenia. <i>Drug, Healthcare and Patient Safety</i> , 2012, 4, 173.	1.0	18
229	Antipsychotic Response in the First Week Predicts Later Efficacy. <i>Neuropsychobiology</i> , 2012, 66, 100-105.	0.9	14
230	Bromperidol decanoate (depot) for schizophrenia. <i>The Cochrane Library</i> , 2012, 11, CD001719.	1.5	2
231	Specialist interventions for homeless people with severe mental illness. <i>The Cochrane Library</i> , 2012, , .	1.5	1
232	Relapse prevention for schizophrenia. <i>The Cochrane Library</i> , 2012, , .	1.5	1
233	Flupenthixol versus placebo for schizophrenia. <i>The Cochrane Library</i> , 2012, 11, CD009777.	1.5	7

#	ARTICLE	IF	CITATIONS
234	Life skills programmes for chronic mental illnesses. The Cochrane Library, 2015, 2015, CD000381.	1.5	25
235	Loxapine inhaler for psychosis-induced aggression or agitation. The Cochrane Library, 0, , .	1.5	12
237	Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). , 2012, 11, CD009377.		50
239	Typical antipsychotics for psychosis in adolescents. The Cochrane Library, 2012, , .	1.5	1
240	Aripiprazole for people with schizophrenia whose illness has been partially responsive to clozapine. The Cochrane Library, 0, , .	1.5	1
242	Quetiapine versus placebo for schizophrenia. The Cochrane Library, 2012, , .	1.5	5
244	Sulpiride dose for schizophrenia. The Cochrane Library, 0, , .	1.5	1
246	Quetiapine for psychosis-induced aggression or agitation. The Cochrane Library, 0, , .	1.5	13
247	Transitional discharge techniques for people with serious mental illness. The Cochrane Library, 2012, , .	1.5	1
251	Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective. Psychological Medicine, 2012, 42, 1461-1473.	2.7	26
255	Cognitive behaviour therapy (group) for schizophrenia. The Cochrane Library, 2012, , .	1.5	7
256	Paliperidone Palmitate for Schizophrenia. Schizophrenia Bulletin, 2012, 38, 1124-1127.	2.3	40
257	Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia. American Journal of Psychiatry, 2012, 169, 1203-1210.	4.0	291
258	Equipercntile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area. European Neuropsychopharmacology, 2012, 22, 501-505.	0.3	26
259	Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia. European Neuropsychopharmacology, 2012, 22, 812-817.	0.3	10
260	A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone. Psychiatry Research, 2012, 198, 194-201.	1.7	13
261	Considering DSM-5: Personality Diagnostics in Patients with Schizophrenia Spectrum Disorders. Psychiatry (New York), 2012, 75, 120-134.	0.3	8
262	Cognitive Behavior Therapy Versus Other Psychosocial Treatments for Schizophrenia. Schizophrenia Bulletin, 2012, 38, 908-910.	2.3	71

#	ARTICLE	IF	CITATIONS
263	Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. The Cochrane Library, 2012, , CD000525.	1.5	25
264	Psychological interventions for psychosis in adolescents. The Cochrane Library, 2012, , .	1.5	1
265	Management of sexual dysfunction due to antipsychotic drug therapy. The Cochrane Library, 2012, 11, CD003546.	1.5	39
267	Acetylcholinesterase inhibitors for schizophrenia. The Cochrane Library, 2012, 1, CD007967.	1.5	39
268	Crisis intervention for people with severe mental illnesses. , 2012, , CD001087.		39
269	Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. Psychiatry Research, 2012, 197, 1-6.	1.7	148
270	Modelling and Simulation of the Positive and Negative Syndrome Scale (PANSS) Time Course and Dropout Hazard in Placebo Arms of Schizophrenia Clinical Trials. Clinical Pharmacokinetics, 2012, 51, 261-275.	1.6	25
271	Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype. Psychological Medicine, 2012, 42, 1865-1871.	2.7	93
272	Poster #207 LONG-TERM FUNCTIONAL IMPROVEMENTS IN THE 2-YEAR TREATMENT OF SCHIZOPHRENIA OUTPATIENTS WITH OLANZAPINE LONG-ACTING INJECTION. Schizophrenia Research, 2012, 136, S165.	1.1	0
273	Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophrenia Research, 2012, 138, 29-34.	1.1	82
274	Maintenance treatment with antipsychotic drugs for schizophrenia. The Cochrane Library, 2012, , CD008016.	1.5	154
276	Paliperidone palmitate for schizophrenia. The Cochrane Library, 2012, , CD008296.	1.5	28
277	Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients's™ and clinicians's™ perspectives in a clinical trial. BMC Medical Research Methodology, 2012, 12, 142.	1.4	3
278	Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry, 2012, 12, 224.	1.1	71
281	Allopurinol and related drugs for schizophrenia. The Cochrane Library, 2012, , .	1.5	1
282	Olanzapine discontinuation for schizophrenia. The Cochrane Library, 0, , .	1.5	1
283	Information and communication technology-based cognitive remediation for supporting treatment compliance for people with serious mental illness. The Cochrane Library, 0, , .	1.5	1
284	Aripiprazole dose for schizophrenia. The Cochrane Library, 0, , .	1.5	0

#	ARTICLE	IF	CITATIONS
287	Asenapine versus typical antipsychotics for schizophrenia. The Cochrane Library, 2012, , .	1.5	2
288	Evidence-based pharmacotherapy of schizophrenia. , 0, , 18-38.		1
289	Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. International Journal of General Medicine, 2012, 5, 391.	0.8	10
290	Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation. Patient Preference and Adherence, 2012, 6, 521.	0.8	7
291	The interrelation of needs and quality of life in first-episode schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 207-216.	1.8	15
292	Can we combine symptom scales for collaborative research projects?. Journal of Psychiatric Research, 2012, 46, 233-238.	1.5	26
293	9-OH risperidone response in risperidone poor responders: An open study of drug response concordance. Neurology Psychiatry and Brain Research, 2012, 18, 109-113.	2.0	2
294	Critical trial-related criteria in acute schizophrenia studies. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 151-155.	1.8	6
295	Empirically driven definitions of “good,” “moderate,” and “poor” levels of functioning in the treatment of schizophrenia. Quality of Life Research, 2013, 22, 2085-2094.	1.5	17
296	Aripiprazole versus other atypical antipsychotics for schizophrenia. , 2013, , CD006569.		18
297	Insight in schizophrenia: associations with empathy. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 299-307.	1.8	48
298	Quetiapine versus typical antipsychotic medications for schizophrenia. The Cochrane Library, 2013, , CD007815.	1.5	23
299	Imputation of response rates from means and standard deviations in schizophrenia. Schizophrenia Research, 2013, 151, 209-214.	1.1	22
300	Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measures. Psychiatry Research, 2013, 209, 291-296.	1.7	14
301	Haloperidol versus placebo for schizophrenia. The Cochrane Library, 2013, , CD003082.	1.5	60
302	Executive functioning in schizophrenia: The result of impairments in lower order cognitive skills?. Schizophrenia Research, 2013, 150, 76-80.	1.1	16
303	Neuroimaging as a potential biomarker to optimize psychiatric research and treatment. International Review of Psychiatry, 2013, 25, 619-631.	1.4	13
304	Psychiatric morbidity, functioning and quality of life in young people at clinical high risk for psychosis. Schizophrenia Research, 2013, 148, 175-180.	1.1	83

#	ARTICLE	IF	CITATIONS
305	Comparing implicit and explicit semantic access of direct and indirect word pairs in schizophrenia to evaluate models of semantic memory. <i>Psychiatry Research</i> , 2013, 205, 199-204.	1.7	10
306	Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression. <i>Journal of Affective Disorders</i> , 2013, 150, 17-22.	2.0	16
307	Intermittent drug techniques for schizophrenia. <i>The Cochrane Library</i> , 2013, , CD006196.	1.5	32
308	Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia. <i>The Cochrane Library</i> , 2013, , CD009546.	1.5	4
309	Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. <i>Schizophrenia Research</i> , 2013, 145, 125-127.	1.1	34
310	Can we inflate effect size and thus increase chances of producing “positive” results if we raise the baseline threshold in schizophrenia trials?. <i>Schizophrenia Research</i> , 2013, 144, 105-108.	1.1	0
311	How to compare doses of different antipsychotics: A systematic review of methods. <i>Schizophrenia Research</i> , 2013, 149, 141-148.	1.1	78
312	Equipercntile linking of the BPRS and the PANSS. <i>European Neuropsychopharmacology</i> , 2013, 23, 956-959.	0.3	101
313	What does the HAMD mean?. <i>Journal of Affective Disorders</i> , 2013, 148, 243-248.	2.0	152
314	The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia. <i>Current Medical Research and Opinion</i> , 2013, 29, 227-239.	0.9	9
315	Sensory processing, neurocognition, and social cognition in schizophrenia: Towards a cohesive cognitive model. <i>Schizophrenia Research</i> , 2013, 146, 209-216.	1.1	21
316	Pharmacogenetics of Risperidone: A Systematic Review of the Clinical Effects of CYP2D6 Polymorphisms. <i>Annals of Pharmacotherapy</i> , 2013, 47, 350-360.	0.9	19
317	A further evaluation of decision-making under risk and under ambiguity in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 249-257.	1.8	53
318	Quetiapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2013, , CD006625.	1.5	44
319	Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial. <i>Trials</i> , 2013, 14, 406.	0.7	15
320	Dance therapy for schizophrenia. <i>The Cochrane Library</i> , 2013, , CD006868.	1.5	43
321	Preventive interventions for postnatal psychosis. <i>The Cochrane Library</i> , 2013, , CD009991.	1.5	6
322	Pimozide for schizophrenia or related psychoses. <i>The Cochrane Library</i> , 2013, , CD001949.	1.5	21



#	ARTICLE	IF	CITATIONS
323	Drawings During Neuropsychiatric Recovery From Anti-NMDA Receptor Encephalitis. American Journal of Psychiatry, 2013, 170, 21-22.	4.0	4
324	Training to Recognize the Early Signs of Recurrence in Schizophrenia. Schizophrenia Bulletin, 2013, 39, 255-256.	2.3	17
325	The treatment outcome of psychotic disorders by traditional healers in central Sudan. International Journal of Social Psychiatry, 2013, 59, 365-376.	1.6	21
326	The relationship between depressive syndrome and suicidal risk in patients with acute schizophrenia. Croatian Medical Journal, 2013, 54, 436-443.	0.2	7
327	Antitherpes Virusâ€“Specific Treatment and Cognition in Schizophrenia: A Test-of-Concept Randomized Double-Blind Placebo-Controlled Trial. Schizophrenia Bulletin, 2013, 39, 857-866.	2.3	43
328	Discriminant analysis of functional optical topography for schizophrenia diagnosis. Journal of Biomedical Optics, 2013, 19, 011006.	1.4	12
329	Add-on Treatment of Benzoate for Schizophrenia. JAMA Psychiatry, 2013, 70, 1267.	6.0	194
330	Psychosocial interventions for people with both severe mental illness and substance misuse. The Cochrane Library, 2013, , CD001088.	1.5	97
331	Should early improvement be reâ€“defined to better predict the maintenance of response in firstâ€“episode schizophrenia patients?. Acta Psychiatrica Scandinavica, 2013, 127, 474-481.	2.2	10
332	Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. International Journal of Methods in Psychiatric Research, 2013, 22, 46-58.	1.1	78
333	Lurasidone versus placebo for schizophrenia. The Cochrane Library, 2013, , .	1.5	0
334	Atypical antipsychotics for psychosis in adolescents. The Cochrane Library, 2013, , CD009582.	1.5	37
335	Attitudes toward menstruation in females with schizophrenia or schizoaffective disorders in Taiwan. Climacteric, 2013, 16, 682-688.	1.1	0
336	To cut a short test even shorter: Reliability and validity of a brief assessment of intellectual ability in Schizophreniaâ€“a control-case family study. Cognitive Neuropsychiatry, 2013, 18, 574-593.	0.7	71
338	Peer support for schizophrenia. The Cochrane Library, 2013, , .	1.5	3
340	A randomized controlled trial of evidence-based supported employment: Nonvocational outcomes. Journal of Vocational Rehabilitation, 2013, 38, 91-98.	0.5	19
342	Training to recognise the early signs of recurrence in schizophrenia. The Cochrane Library, 2013, , CD005147.	1.5	27
344	Haloperidol dose for the acute phase of schizophrenia. The Cochrane Library, 2013, , CD001951.	1.5	20

#	ARTICLE	IF	CITATIONS
346	Nidotherapy for people with schizophrenia. The Cochrane Library, 2013, , CD009929.	1.5	1
348	Fluphenazine (oral) versus placebo for schizophrenia. The Cochrane Library, 2013, , CD006352.	1.5	12
349	Animal-assisted therapy for people with serious mental illness. The Cochrane Library, 0, , .	1.5	3
350	Comparing Symptom Response Among Antipsychotic Medications in CATIE. Journal of Clinical Psychopharmacology, 2013, 33, 123-126.	0.7	2
351	Aripiprazole for neuroleptic induced hyperprolactinaemia. The Cochrane Library, 0, , .	1.5	1
353	Memantine for schizophrenia. The Cochrane Library, 2013, , .	1.5	1
355	Emotion-Related Visual Mismatch Responses in Schizophrenia: Impairments and Correlations with Emotion Recognition. PLoS ONE, 2013, 8, e75444.	1.1	50
356	Zotepine versus placebo for schizophrenia. The Cochrane Library, 0, , .	1.5	5
357	Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection. Neuropsychiatric Disease and Treatment, 2014, 10, 1125.	1.0	5
358	Elevated Levels of Plasma Phenylalanine in Schizophrenia: A Guanosine Triphosphate Cyclohydrolase-1 Metabolic Pathway Abnormality?. PLoS ONE, 2014, 9, e85945.	1.1	19
359	Anticholinergics (various) for neuroleptic-induced parkinsonism. The Cochrane Library, 2014, , .	1.5	1
360	Pharmacological interventions for reducing weight gain in schizophrenia. The Cochrane Library, 0, , .	1.5	4
361	Anticholinergics versus placebo for neuroleptic-induced parkinsonism. The Cochrane Library, 2014, , .	1.5	3
362	Haloperidol discontinuation for schizophrenia. The Cochrane Library, 2014, , .	1.5	1
364	Implementation of treatment guidelines for specialist mental health care. , 2014, , CD009780.		26
365	Pericyazine for schizophrenia. The Cochrane Library, 2014, , CD007479.	1.5	5
366	Psychosocial Interventions for People With Both Severe Mental Illness and Substance Misuse. Schizophrenia Bulletin, 2014, 40, 18-20.	2.3	93
367	Association between schizophrenia symptoms and neurocognition on mobility in older adults with schizophrenia. Aging and Mental Health, 2014, 18, 1006-1012.	1.5	12

#	ARTICLE	IF	CITATIONS
368	Substance use in people at clinical high-risk for psychosis. BMC Psychiatry, 2014, 14, 361.	1.1	8
369	Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. The Cochrane Library, 2014, 2014, CD009268.	1.5	31
370	Implementation of Treatment Guidelines for Specialist Mental Health Care. Schizophrenia Bulletin, 2014, 40, 737-739.	2.3	44
371	Acupuncture for Schizophrenia. Schizophrenia Bulletin, 2014, 40, 1198-1199.	2.3	21
372	Trauma history characteristics associated with mental states at clinical high risk for psychosis. Psychiatry Research, 2014, 220, 237-244.	1.7	36
373	Event-related theta synchronization predicts deficit in facial affect recognition in schizophrenia.. Journal of Abnormal Psychology, 2014, 123, 178-189.	2.0	19
374	Compulsory community and involuntary outpatient treatment for people with severe mental disorders. , 2014, , CD004408.		111
375	Chlorpromazine versus placebo for schizophrenia. The Cochrane Library, 2015, 2015, CD000284.	1.5	73
376	Carbamazepine for schizophrenia. The Cochrane Library, 2014, , CD001258.	1.5	26
377	Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. , 2014, , CD010646.		11
378	Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D. British Journal of Psychiatry, 2014, 205, 236-243.	1.7	95
379	Category fluency in schizophrenia research: Is it an executive or semantic measure?. Cognitive Neuropsychiatry, 2014, 19, 81-95.	0.7	20
380	The <sc>MMPI</sc>â€² in chronic psychiatric illness. Scandinavian Journal of Psychology, 2014, 55, 513-519.	0.8	9
381	Trajectories of antipsychotic response in drugâ€naïve schizophrenia patients: results from the 6â€month <sc>ESPASS</sc> followâ€up study. Acta Psychiatrica Scandinavica, 2014, 129, 116-125.	2.2	20
382	Treatments for primary delusional infestation. The Cochrane Library, 2014, , .	1.5	5
383	Family intervention (brief) for schizophrenia. The Cochrane Library, 2014, 2014, CD009802.	1.5	30
384	Associations of Schizophrenia Symptoms and Neurocognition With Physical Activity in Older Adults With Schizophrenia. Biological Research for Nursing, 2014, 16, 23-30.	1.0	39
385	Cannabis and schizophrenia. The Cochrane Library, 2014, 2014, CD004837.	1.5	44

#	ARTICLE	IF	CITATIONS
386	Brief Family Intervention for Schizophrenia. Schizophrenia Bulletin, 2014, 40, 497-498.	2.3	4
387	Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology, 2014, 29, 322-331.	0.9	25
388	Maladaptive Personality Traits Increase Subjectively During the Course of Schizophrenia Spectrum Disorders. Journal of Nervous and Mental Disease, 2014, 202, 319-323.	0.5	3
389	Population Pharmacokinetic/Pharmacodynamic Model of Clozapine for Characterizing the Relationship Between Accumulated Exposure and PANSS Scores in Patients With Schizophrenia. Therapeutic Drug Monitoring, 2014, 36, 378-386.	1.0	16
390	Noninferiority of Perphenazine vs. Three Second-Generation Antipsychotics in Chronic Schizophrenia. Journal of Nervous and Mental Disease, 2014, 202, 18-24.	0.5	10
391	Early improvement as a predictor of treatment response and remission in patients with schizophrenia: A pooled, post-hoc analysis from the asenapine development program. Journal of Psychopharmacology, 2014, 28, 387-394.	2.0	29
392	Early Perception of Medication Benefit Predicts Subsequent Antipsychotic Response in Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2014, 8, 84-90A.	1.4	4
393	Paliperidone Palmitate versus Risperidone Long-Acting Injection in Markedly-to-Severely Ill Schizophrenia Subjects. Clinical Schizophrenia and Related Psychoses, 2014, 8, 101-109A.	1.4	9
394	The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis. International Clinical Psychopharmacology, 2014, 29, 77-85.	0.9	9
395	Impaired Cerebellar-Dependent Eyeblink Conditioning in First-Degree Relatives of Individuals With Schizophrenia. Schizophrenia Bulletin, 2014, 40, 1001-1010.	2.3	20
396	Aripiprazole versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2014, , CD006569.	1.5	70
397	Atomoxetine for schizophrenia. The Cochrane Library, 0, , .	1.5	1
398	Acupuncture for schizophrenia. The Cochrane Library, 2014, 2014, CD005475.	1.5	18
399	Virtual reality for treatment compliance for people with serious mental illness. The Cochrane Library, 2014, , CD009928.	1.5	25
400	Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. The Cochrane Library, 2014, , CD009369.	1.5	7
401	Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. The Cochrane Library, 2014, 2014, CD001470.	1.5	9
402	Trifluoperazine versus placebo for schizophrenia. The Cochrane Library, 2014, , CD010226.	1.5	12
403	Facial emotion recognition in paranoid schizophrenia and autism spectrum disorder. Schizophrenia Research, 2014, 159, 509-514.	1.1	36

#	ARTICLE	IF	CITATIONS
404	Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. The Cochrane Library, 2014, , CD009396.	1.5	12
405	Cognitive therapy for patients with schizophrenia. Lancet, The, 2014, 384, 400.	6.3	1
406	The impact of immigration and visible minority status on psychosis symptom profile. Social Psychiatry and Psychiatric Epidemiology, 2014, 49, 1747-1757.	1.6	21
407	Comparing PANSS scores and corresponding CGI scores between stable and acute schizophrenic patients. Schizophrenia Research, 2014, 152, 307-308.	1.1	5
408	Theory of mind impairments in patients with deficit schizophrenia. Comprehensive Psychiatry, 2014, 55, 349-356.	1.5	24
409	A pilot study on the effects of cognitive remediation on hemodynamic responses in the prefrontal cortices of patients with schizophrenia: A multi-channel near-infrared spectroscopy study. Schizophrenia Research, 2014, 153, 87-95.	1.1	27
410	Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet, The, 2014, 383, 1395-1403.	6.3	196
411	Prefrontal glutamate levels differentiate early phase schizophrenia and methamphetamine addiction: A 1H MRS study at 3Tesla. Schizophrenia Research, 2014, 157, 231-237.	1.1	28
412	Disruption of structureâ€“function coupling in the schizophrenia connectome. NeuroImage: Clinical, 2014, 4, 779-787.	1.4	124
414	Measurements of Response, Remission, and Recovery in Schizophrenia and Examples for Their Clinical Application. Journal of Clinical Psychiatry, 2014, 75, 8-14.	1.1	113
415	Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. The Cochrane Library, 0, , .	1.5	1
416	Flexible-dose oral paliperidone ER in non-acute schizophrenia previously unsuccessfully treated with oral risperidone. Clinical Practice (London, England), 2014, 11, 573-583.	0.1	1
417	Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. The Cochrane Library, 2014, 2014, CD009230.	1.5	17
418	HIV prevention advice for people with serious mental illness. , 2014, , CD009639.		5
419	Anticholinergics for neuroleptic-induced parkinsonism and tardive dyskinesia. The Cochrane Library, 2014, , .	1.5	1
420	Length of hospitalisation for people with severe mental illness. The Cochrane Library, 2014, 2014, CD000384.	1.5	50
421	Physical health care monitoring for people with serious mental illness. The Cochrane Library, 2014, 2014, CD008298.	1.5	20
422	Perazine for schizophrenia. The Cochrane Library, 2014, 2014, CD002832.	1.5	5

#	ARTICLE	IF	CITATIONS
423	Horticultural therapy for schizophrenia. The Cochrane Library, 2014, , CD009413.	1.5	10
424	General physical health advice for people with serious mental illness. The Cochrane Library, 2014, 2014, CD008567.	1.5	14
425	Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. The Cochrane Library, 2014, , CD009227.	1.5	5
426	Information and communication technology based prompting for treatment compliance for people with serious mental illness. The Cochrane Library, 2014, 2014, CD009960.	1.5	20
427	Sulpiride versus placebo for schizophrenia. The Cochrane Library, 2014, , CD007811.	1.5	8
428	Motivation and Social Cognition in Patients with Schizophrenia. Journal of the International Neuropsychological Society, 2015, 21, 436-443.	1.2	16
429	Perphenazine for schizophrenia. The Cochrane Library, 2015, 2015, CD003443.	1.5	15
430	Fluphenazine decanoate (depot) and enanthate for schizophrenia. The Cochrane Library, 2016, 2016, CD000307.	1.5	11
432	Treatments for delusional disorder. The Cochrane Library, 2015, 2015, CD009785.	1.5	24
433	Unilateral electroconvulsive therapy versus bilateral electroconvulsive therapy for schizophrenia. The Cochrane Library, 0, , .	1.5	0
434	The relationship between stigma sentiments and self-identity of individuals with schizophrenia.. Psychiatric Rehabilitation Journal, 2015, 38, 125-131.	0.8	15
436	Zuclopenthixol versus placebo for schizophrenia. The Cochrane Library, 2015, 2015, CD010598.	1.5	2
438	Acceptance and Commitment Therapy for schizophrenia and related disorders. The Cochrane Library, 0, , .	1.5	3
439	Supportive therapy for schizophrenia. The Cochrane Library, 2017, 2017, CD004716.	1.5	25
440	Self-help and guided self-help interventions for schizophrenia and related disorders. The Cochrane Library, 2015, , .	1.5	4
441	Increasing antipsychotic dose for non response in schizophrenia. The Cochrane Library, 0, , .	1.5	2
442	Yoga versus standard care for schizophrenia. The Cochrane Library, 2015, 2015, CD010554.	1.5	32
443	Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. The Cochrane Library, 2015, 2015, CD010646.	1.5	14

#	ARTICLE	IF	CITATIONS
444	Avatar therapy for schizophrenia or related disorders. The Cochrane Library, 0, , .	1.5	5
445	Tai chi for schizophrenia. The Cochrane Library, 2015, , .	1.5	2
446	Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. Canadian Journal of Psychiatry, 2015, 60, 515-522.	0.9	35
447	Prediction of Response to Antipsychotic Drugs in Schizophrenia Patients within the Early Phase of Treatment. Journal of Microbiology and Biotechnology, 2015, 25, 390-398.	0.9	3
448	Rating scales measuring the severity of psychotic depression. Acta Psychiatrica Scandinavica, 2015, 132, 335-344.	2.2	17
449	Switching antipsychotic for non response in schizophrenia. The Cochrane Library, 2015, , .	1.5	0
450	Lithium for schizophrenia. The Cochrane Library, 2015, 2015, CD003834.	1.5	57
451	Asenapine versus placebo for schizophrenia. The Cochrane Library, 2015, , CD011458.	1.5	7
452	Electroconvulsive therapy for treatment-resistant schizophrenia. The Cochrane Library, 2015, , .	1.5	1
453	Crisis intervention for people with severe mental illnesses. The Cochrane Library, 2015, 2015, CD001087.	1.5	125
454	Transcranial magnetic stimulation (TMS) for schizophrenia. The Cochrane Library, 2015, 2015, CD006081.	1.5	37
456	Generic Olanzapine Substitution in Patients With Schizophrenia. Therapeutic Drug Monitoring, 2015, 37, 827-830.	1.0	8
457	Positive Symptoms Are Associated With Clinicians's™ Global Impression in Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology, 2015, 35, 237-241.	0.7	4
458	Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study. Neuropsychiatric Disease and Treatment, 2016, 12, 15.	1.0	18
459	Patterns of clozapine and other antipsychotics prescriptions in patients with treatment-resistant schizophrenia in community mental health centers in São Paulo, Brazil. Revista De Psiquiatria Clinica, 2015, 42, 165-170.	0.6	11
460	Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. The Cochrane Library, 2015, , .	1.5	2
461	Amphetamines versus placebo for schizophrenia. The Cochrane Library, 0, , .	1.5	0
463	Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?. Neuropsychiatric Disease and Treatment, 2015, 11, 2471.	1.0	18

#	ARTICLE	IF	CITATIONS
465	Acetophenazine versus chlorpromazine for schizophrenia. The Cochrane Library, 0, , .	1.5	8
466	Chlorpromazine versus piperacetazine for schizophrenia. The Cochrane Library, 0, , .	1.5	9
467	lloperidone versus placebo for schizophrenia. The Cochrane Library, 2015, , .	1.5	1
468	Pharmacological interventions for acute and transient psychotic disorder (ATPD). The Cochrane Library, 2015, , .	1.5	2
469	NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: THE PREVAILING CHALLENGES. Journal of Health and Allied Sciences NU, 2015, 05, 104-115.	0.1	1
470	Initial Severity of Schizophrenia and Efficacy of Antipsychotics. JAMA Psychiatry, 2015, 72, 14.	6.0	94
471	The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: An analysis of the CATIE Schizophrenia Trial. Schizophrenia Research, 2015, 166, 110-114.	1.1	11
472	First-Rank Symptoms and Premorbid Adjustment in Young Individuals at Increased Risk of Developing Psychosis. Psychopathology, 2015, 48, 120-126.	1.1	20
473	Dealing with feeling: Specific emotion regulation skills predict responses to stress in psychosis. Psychiatry Research, 2015, 228, 216-222.	1.7	42
474	Quetiapine immediate release <i>v.</i> placebo for schizophrenia: systematic review, meta-analysis and reappraisal. British Journal of Psychiatry, 2015, 206, 360-370.	1.7	11
475	The relationship between cognitive insight and quality of life in schizophrenia spectrum disorders: Symptom severity as potential moderator. Psychiatry Research, 2015, 230, 839-845.	1.7	30
476	Relationship of serum levels of TNF- $\alpha$ , IL-6 and IL-18 and schizophrenia-like symptoms in chronic ketamine abusers. Schizophrenia Research, 2015, 169, 10-15.	1.1	13
477	Insight in inpatients with schizophrenia: Relationship to symptoms and neuropsychological functioning. Schizophrenia Research, 2015, 161, 376-381.	1.1	40
478	Hostile attributions in bipolar disorder and schizophrenia contribute to poor social functioning. Acta Psychiatrica Scandinavica, 2015, 131, 472-482.	2.2	78
479	Relationship between the Rorschach Perceptual Thinking Index (PTI) and the Positive and Negative Syndrome Scale (PANSS) in psychotic patients: A validity study. Psychiatry Research, 2015, 225, 315-321.	1.7	12
480	Reasons for cannabis use in first-episode psychosis: Does strength of endorsement change over 12 months?. European Psychiatry, 2015, 30, 152-159.	0.1	21
481	Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms. Schizophrenia Research, 2015, 162, 169-174.	1.1	26
482	Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. The Cochrane Library, 2015, 2015, CD009831.	1.5	52



#	ARTICLE	IF	CITATIONS
483	On the use of the Positive and Negative Syndrome Scale in randomized clinical trials. Schizophrenia Research, 2015, 165, 181-187.	1.1	20
484	Relationships between global assessment of functioning and other rating scales in clinical trials for schizophrenia. Psychiatry Research, 2015, 227, 265-269.	1.7	40
485	The effects of switching from oral to LAI antipsychotic treatment on subjective experience of schizophrenic and schizoaffective patients: Preliminary results. International Journal of Psychiatry in Clinical Practice, 2015, 19, 106-113.	1.2	10
486	Caregiver distress in first-episode psychosis: the role of subjective appraisal, over-involvement and symptomatology. Social Psychiatry and Psychiatric Epidemiology, 2015, 50, 371-378.	1.6	30
487	Psychoeducation (brief) for people with serious mental illness. The Cochrane Library, 2015, , CD010823.	1.5	66
488	The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial. Trials, 2015, 16, 71.	0.7	8
489	Psychoeducation for siblings of people with severe mental illness. The Cochrane Library, 2015, 2015, CD010540.	1.5	18
490	Relationship Between Symptomatic Improvement and Overall Illness Severity in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2015, 35, 128-133.	0.7	5
491	Abnormalities in Hemispheric Specialization of Caudate Nucleus Connectivity in Schizophrenia. JAMA Psychiatry, 2015, 72, 552.	6.0	63
492	Understanding the trauma of first-episode psychosis. Microbial Biotechnology, 2015, 9, 211-220.	0.9	28
493	Social skills programmes for schizophrenia. The Cochrane Library, 2015, , CD009006.	1.5	52
494	Failure to use corollary discharge to remap visual target locations is associated with psychotic symptom severity in schizophrenia. Journal of Neurophysiology, 2015, 114, 1129-1136.	0.9	28
495	Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences. Contemporary Clinical Trials, 2015, 43, 60-62.	0.8	95
496	Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Molecular Psychiatry, 2015, 20, 695-702.	4.1	128
497	Interventions for antipsychotic-induced amenorrhoea. The Cochrane Library, 2016, , .	1.5	1
498	Distinctive Rorschach profiles of young adults with schizophrenia and autism spectrum disorder. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2403-2410.	1.0	11
499	Social dysfunction and skills in schizophrenia: relationship with treatment response and severity of psychopathology. Revista De Psiquiatria Clinica, 2016, 43, 107-111.	0.6	3
500	How Do Psychiatrists Apply the Minimum Clinically Important Difference to Assess Patient Responses to Treatment?. MDM Policy and Practice, 2016, 1, 238146831667885.	0.5	2

#	ARTICLE	IF	CITATIONS
501	Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia. PLoS ONE, 2016, 11, e0148539.	1.1	19
502	The Use of the Health of the Nation Outcome Scales for Assessing Functional Change in Treatment Outcome Monitoring of Patients with Chronic Schizophrenia. Frontiers in Public Health, 2016, 4, 220.	1.3	5
503	Aripiprazole versus perphenazine for people with schizophrenia and schizophrenia-like psychoses. The Cochrane Library, 0, , .	1.5	0
504	Aripiprazole versus sulpiride for people with schizophrenia and schizophrenia-like psychoses. The Cochrane Library, 0, , .	1.5	0
505	Acetylsalicylic acid (aspirin) for schizophrenia. The Cochrane Library, 0, , .	1.5	3
506	Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia. Human Psychopharmacology, 2016, 31, 325-331.	0.7	16
507	Challenging the understanding of significant improvement and outcome in schizophrenia – the concept of reliable and clinically significant change methods. International Journal of Methods in Psychiatric Research, 2016, 25, 3-11.	1.1	5
508	Risk assessment for aggressive behaviour in schizophrenia. The Cochrane Library, 2016, , .	1.5	3
509	Aripiprazole versus haloperidol for people with schizophrenia and schizophrenia-like psychoses. The Cochrane Library, 2016, , .	1.5	3
511	Cariprazine versus placebo for schizophrenia. The Cochrane Library, 2016, , .	1.5	1
512	Implementation of treatment guidelines for specialist mental health care. The Cochrane Library, 2016, 12, CD009780.	1.5	29
513	Risperidone versus placebo for schizophrenia. The Cochrane Library, 2016, 12, CD006918.	1.5	24
514	Droperidol for psychosis-induced aggression or agitation. The Cochrane Library, 2016, 2016, CD002830.	1.5	24
515	Aripiprazole versus chlorpromazine for people with schizophrenia and schizophrenia-like psychoses. The Cochrane Library, 0, , .	1.5	1
516	Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder. Journal of Clinical Psychopharmacology, 2016, 36, 372-376.	0.7	9
517	A Systematic Review on the Pharmacological Treatment of Delusional Disorder. Journal of Clinical Psychopharmacology, 2016, 36, 684-690.	0.7	28
518	Treatment-Resistant Schizophrenia. Psychiatric Clinics of North America, 2016, 39, 239-265.	0.7	123
519	Obtaining employment as an anchor for estimating the minimum clinically important difference on the Positive and Negative Syndrome Scale (PANSS) in schizophrenia. Psychiatry Research, 2016, 238, 304-309.	1.7	7

#	ARTICLE	IF	CITATIONS
520	Significant treatment effect of adjunct music therapy to standard treatment on the positive, negative, and mood symptoms of schizophrenic patients: a meta-analysis. BMC Psychiatry, 2016, 16, 16.	1.1	30
521	Antioxidant treatments for schizophrenia. The Cochrane Library, 2016, 2016, CD008919.	1.5	49
522	Are obstetrical complications really involved in the etiology and course of schizophrenia and mood disorders?. Psychiatry Research, 2016, 241, 297-301.	1.7	23
524	The "Insight Paradox" in Schizophrenia: Magnitude, Moderators and Mediators of the Association Between Insight and Depression. Schizophrenia Bulletin, 2016, 42, 1225-1233.	2.3	61
525	Cariprazine in the treatment of schizophrenia. International Clinical Psychopharmacology, 2016, 31, 61-68.	0.9	56
526	Clinical Characteristics and Predictors of Outcome of Schizophrenia-Spectrum Psychosis in Children and Adolescents: A Systematic Review. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 410-427.	0.7	104
527	Clinical and cognitive insight in patients with acute-phase psychosis: Association with treatment and neuropsychological functioning. Nordic Journal of Psychiatry, 2016, 70, 528-535.	0.7	14
528	Brief Questionnaire Derived from PANSS Using a General Probability Model to Assess and Monitor the Clinical Features of Schizophrenia. Pharmacopsychiatry, 2016, 49, 117-123.	1.7	1
530	Oral health education (advice and training) for people with serious mental illness. The Cochrane Library, 2016, 9, CD008802.	1.5	15
531	The latent structure of psychiatric symptoms across mental disorders as measured with the PANSS and BPRS-18. Psychiatry Research, 2016, 245, 83-90.	1.7	16
532	HIV prevention advice for people with serious mental illness. The Cochrane Library, 2016, 9, CD009639.	1.5	5
533	Long-acting aripiprazole (depot) versus placebo for schizophrenia. The Cochrane Library, 0, , .	1.5	0
535	Smoking cessation advice for people with serious mental illness. The Cochrane Library, 2016, 2016, CD009704.	1.5	15
536	Adjunctive varenicline treatment for smoking reduction in patients with schizophrenia: A randomized double-blind placebo-controlled trial. Schizophrenia Research, 2016, 176, 206-211.	1.1	10
537	Reliability of a patient-reported outcome measure in schizophrenia: Results from back-to-back self-ratings. Psychiatry Research, 2016, 244, 415-419.	1.7	14
538	Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. The Cochrane Library, 2016, 2016, CD010832.	1.5	4
539	Haloperidol for long-term aggression in psychosis. The Cochrane Library, 2016, 2016, CD009830.	1.5	17
540	Haloperidol plus promethazine for psychosis-induced aggression. The Cochrane Library, 2016, 2016, CD005146.	1.5	51

#	ARTICLE	IF	CITATIONS
541	Valproate for schizophrenia. The Cochrane Library, 2016, 2016, CD004028.	1.5	65
542	Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia. The Cochrane Library, 0, , .	1.5	3
543	Validity and Reliability of the Arabic Version of the Positive and Negative Syndrome Scale. Psychopathology, 2016, 49, 181-187.	1.1	16
544	LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment. European Psychiatry, 2016, 37, 35-42.	0.1	12
545	Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women. JAMA Psychiatry, 2016, 73, 947.	6.0	74
546	Pharmacological interventions for clozapine-induced sinus tachycardia. The Cochrane Library, 2016, 2016, CD011566.	1.5	9
547	Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. Focus (American Psychiatric Publishing), 2016, 14, 396-402.	0.4	3
548	Bifeprunox versus placebo for schizophrenia. The Cochrane Library, 2016, 2016, CD012029.	1.5	4
550	Open Dialogue for psychosis or severe mental illness. The Cochrane Library, 2016, , .	1.5	1
551	Comparison of burden among family members of patients diagnosed with schizophrenia and bipolar disorder in a large acute psychiatric hospital in China. BMC Psychiatry, 2016, 16, 283.	1.1	32
552	Activity monitoring using a mHealth device and correlations with psychopathology in patients with chronic schizophrenia. Psychiatry Research, 2016, 246, 712-718.	1.7	19
553	Effects of Psychoeducation Given to Caregivers of People With a Diagnosis of Schizophrenia. Issues in Mental Health Nursing, 2016, 37, 800-810.	0.6	16
554	Adjunctive Peony-Glycyrrhiza Decoction for antipsychotic-induced hyperprolactinemia. The Cochrane Library, 0, , .	1.5	1
555	Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial. BMC Psychiatry, 2016, 16, 280.	1.1	16
556	A randomised controlled trial of the clinical and cost-effectiveness of a contingency management intervention compared to treatment as usual for reduction of cannabis use and of relapse in early psychosis (CIRCLE): a study protocol for a randomised controlled trial. Trials, 2016, 17, 515.	0.7	7
557	Lurasidone versus typical antipsychotics for schizophrenia. The Cochrane Library, 2016, , .	1.5	0
558	Gene-expression analysis of clozapine treatment in whole blood of patients with psychosis. Psychiatric Genetics, 2016, 26, 211-217.	0.6	9
559	Prescribing Practice in Inpatients Versus Outpatients With Schizophrenia Initiating Treatment With Second-Generation Antipsychotics. Journal of Clinical Psychopharmacology, 2016, 36, 621-627.	0.7	4

#	ARTICLE	IF	CITATIONS
560	Acetyl-L-Carnitine Augmentation of Clozapine in Partial-Responder Schizophrenia: A 12-Week, Open-Label Uncontrolled Preliminary Study. <i>Clinical Neuropharmacology</i> , 2016, 39, 277-280.	0.2	19
561	Antiglucocorticoid and related treatments for psychosis. <i>The Cochrane Library</i> , 2016, 2016, CD006995.	1.5	13
562	Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2016, 2016, CD010631.	1.5	23
563	Chlorpromazine versus reserpine for schizophrenia. <i>The Cochrane Library</i> , 2016, 4, CD012122.	1.5	11
564	Early interventions for prodromal stage of psychosis. <i>The Cochrane Library</i> , 2016, , .	1.5	3
565	Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis. <i>BMC Psychiatry</i> , 2016, 16, 90.	1.1	38
566	Task-independent effects are potential confounders in longitudinal imaging studies of learning in schizophrenia. <i>NeuroImage: Clinical</i> , 2016, 10, 159-171.	1.4	2
567	Validation of the 17-item <scp>Hamilton Depression Rating Scale</scp> definition of response for adults with major depressive disorder using equipercentile linking to <scp>Clinical Global Impression</scp> scale ratings: analysis of <scp>Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study</scp> (PGRN&AMP;S) data. <i>Human Psychopharmacology</i> , 2016, 31, 185-192.	0.7	60
568	Sleep disorders in patients with depression or schizophrenia: A randomized controlled trial using acupuncture treatment. <i>European Journal of Integrative Medicine</i> , 2016, 8, 789-796.	0.8	4
569	Risperidone (depot) for schizophrenia. <i>The Cochrane Library</i> , 2016, 4, CD004161.	1.5	16
570	Dietary advice for people with schizophrenia. <i>The Cochrane Library</i> , 2016, 2016, CD009547.	1.5	8
571	A Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral Olanzapine. <i>Journal of Psychiatric Practice</i> , 2016, 22, 9-21.	0.3	4
572	A Retrospective Investigation of Clozapine Treatment in Autistic and Nonautistic Children and Adolescents in an Inpatient Clinic in Turkey. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 815-821.	0.7	15
573	Role of sICAM-1 and sVCAM-1 as biomarkers in early and late stages of schizophrenia. <i>Journal of Psychiatric Research</i> , 2016, 73, 45-52.	1.5	23
574	Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia. <i>Medicine (United States)</i> , 2016, 95, e2475.	0.4	27
575	Cost-Effectiveness of Comprehensive, Integrated Care for First Episode Psychosis in the NIMH RAISE Early Treatment Program. <i>Schizophrenia Bulletin</i> , 2016, 42, 896-906.	2.3	111
576	Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 921-936.	0.9	26
577	A cluster-analytical approach toward real-world outcome in outpatients with stable schizophrenia. <i>European Psychiatry</i> , 2016, 32, 48-54.	0.1	29

#	ARTICLE	IF	CITATIONS
578	Mental simulation and experience as determinants of performance expectancies in people with schizophrenia spectrum disorder. <i>Psychiatry Research</i> , 2016, 237, 97-102.	1.7	6
579	Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users. <i>Psychiatry Research</i> , 2016, 237, 311-315.	1.7	37
580	Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 210-220.	1.3	4
581	Plasma metabonomics study of first-Episode schizophrenia treated with olanzapine in female patients. <i>Neuroscience Letters</i> , 2016, 617, 270-276.	1.0	12
582	Deep neural network with weight sparsity control and pre-training extracts hierarchical features and enhances classification performance: Evidence from whole-brain resting-state functional connectivity patterns of schizophrenia. <i>NeuroImage</i> , 2016, 124, 127-146.	2.1	295
583	Sleep in schizophrenia: A systematic review and meta-analysis of polysomnographic findings in case-control studies. <i>Sleep Medicine Reviews</i> , 2017, 32, 69-84.	3.8	118
584	Acceptance and Commitment Therapy for Posttraumatic Stress Disorder in Early Psychosis: A Case Series. <i>Cognitive and Behavioral Practice</i> , 2017, 24, 187-199.	0.9	15
585	What does the MADRS mean? Equipercentile linking with the CGI using a company database of mirtazapine studies. <i>Journal of Affective Disorders</i> , 2017, 210, 287-293.	2.0	45
586	Predictors and mediators of trait anger across the psychosis continuum: The role of attachment style, paranoia and social cognition. <i>Psychiatry Research</i> , 2017, 249, 132-138.	1.7	8
587	Intensive case management for severe mental illness. <i>The Cochrane Library</i> , 2017, 2017, CD007906.	1.5	112
588	MKT+. , 2017, , .		5
589	Psychological interventions for post-traumatic stress disorder (PTSD) in people with severe mental illness. <i>The Cochrane Library</i> , 2017, 2017, CD011464.	1.5	37
590	Ginkgo biloba versus placebo for schizophrenia. <i>The Cochrane Library</i> , 0, , .	1.5	0
591	Decreased Cingulate Cortex activation during cognitive control processing in bipolar disorder. <i>Journal of Affective Disorders</i> , 2017, 213, 86-95.	2.0	19
592	Representativeness of clinical PET study participants with schizophrenia: A systematic review. <i>Journal of Psychiatric Research</i> , 2017, 88, 72-79.	1.5	6
593	Cerebral blood flow autoregulation is impaired in schizophrenia: A pilot study. <i>Schizophrenia Research</i> , 2017, 188, 63-67.	1.1	8
594	Blonanserin versus risperidone for schizophrenia. <i>The Cochrane Library</i> , 2017, , .	1.5	0
595	Chlorpromazine dose for people with schizophrenia. <i>The Cochrane Library</i> , 2017, 2017, CD007778.	1.5	19

#	ARTICLE	IF	CITATIONS
596	Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2017, 32, 235-248.	0.9	19
597	<i>Toxoplasma gondii</i> and schizophrenia: a review of published RCTs. <i>Parasitology Research</i> , 2017, 116, 1793-1799.	0.6	31
598	Validation of the Five-Factor Model of the Arabic Version of the Positive and Negative Syndrome Scale in Schizophrenia. <i>Psychopathology</i> , 2017, 50, 211-218.	1.1	7
599	One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. <i>British Journal of Psychiatry</i> , 2017, 211, 137-143.	1.7	33
600	Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. <i>American Journal of Psychiatry</i> , 2017, 174, 927-942.	4.0	338
601	Music therapy for people with schizophrenia and schizophrenia-like disorders. <i>The Cochrane Library</i> , 2017, 2017, CD004025.	1.5	123
602	Clozapine dose for schizophrenia. <i>The Cochrane Library</i> , 2017, 2017, CD009555.	1.5	33
603	Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. <i>The Cochrane Library</i> , 2017, 2017, CD006324.	1.5	58
604	Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation. <i>Schizophrenia Research</i> , 2017, 190, 115-120.	1.1	12
605	Chlorpromazine versus metiapine for schizophrenia. <i>The Cochrane Library</i> , 2017, 2017, CD011655.	1.5	9
606	De-escalation techniques for psychosis-induced aggression or agitation. <i>The Cochrane Library</i> , 2017, 2017, CD009922.	1.5	27
607	Compulsory community and involuntary outpatient treatment for people with severe mental disorders. <i>The Cochrane Library</i> , 2017, 2017, CD004408.	1.5	64
608	The Beliefs about Paranoia Scale: Confirmatory factor analysis and tests of a metacognitive model of paranoia in a clinical sample. <i>Psychiatry Research</i> , 2017, 248, 87-94.	1.7	8
609	Effects of self and familiarity on change detection in patients with schizophrenia. <i>Psychiatry Research</i> , 2017, 248, 140-146.	1.7	4
610	Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. <i>The Cochrane Library</i> , 2017, 2017, CD011707.	1.5	7
611	Risperidone (oral forms) for people with schizophrenia. <i>The Cochrane Library</i> , 2017, , .	1.5	1
612	Fluphenazine (dose) for people with schizophrenia. <i>The Cochrane Library</i> , 2017, , .	1.5	1
613	The recovery of factors associated with decision-making capacity in individuals with psychosis. <i>BJPsych Open</i> , 2017, 3, 113-119.	0.3	11



#	ARTICLE	IF	CITATIONS
614	Yoga versus non-standard care for schizophrenia. The Cochrane Library, 2017, 2017, CD012052.	1.5	18
615	Fluphenazine decanoate (timing of administration) for people with schizophrenia. The Cochrane Library, 2017, , .	1.5	1
616	Aripiprazole versus ziprasidone for schizophrenia. The Cochrane Library, 2017, , .	1.5	0
617	Anticholinergic discontinuation for antipsychotic-induced extra-pyramidal symptoms. The Cochrane Library, 2017, , .	1.5	1
618	Chlorpromazine versus penfluridol for schizophrenia. The Cochrane Library, 2017, 2017, CD011831.	1.5	11
619	Non-clozapine antipsychotic combinations for treatment-resistant schizophrenia. The Cochrane Library, 0, , .	1.5	1
620	Communication skills training for mental health professionals working with people with severe mental illness. The Cochrane Library, 2017, 2017, CD010006.	1.5	20
621	Magnetic seizure therapy for people with schizophrenia. The Cochrane Library, 2017, , .	1.5	0
622	Haloperidol versus risperidone for schizophrenia. The Cochrane Library, 2017, , .	1.5	2
623	Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). The Cochrane Library, 2017, 2017, CD009377.	1.5	73
624	Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses. BJPsych Open, 2017, 3, 285-290.	0.3	7
625	Cognitive remediation therapy plus standard care versus standard care for people with schizophrenia. The Cochrane Library, 2017, , .	1.5	0
626	Zuclopenthixol dihydrochloride for schizophrenia. The Cochrane Library, 2017, 11, CD005474.	1.5	13
627	Antipsychotic combinations for schizophrenia. The Cochrane Library, 2017, 2017, CD009005.	1.5	28
628	Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study. Nordic Journal of Psychiatry, 2017, 71, 513-520.	0.7	18
629	Ventricular volumes across stages of schizophrenia and other psychoses. Australian and New Zealand Journal of Psychiatry, 2017, 51, 1041-1051.	1.3	17
630	The facial expression of schizophrenic patients applied with infrared thermal facial image sequence. BMC Psychiatry, 2017, 17, 229.	1.1	17
631	Wendan decoction (Traditional Chinese medicine) for schizophrenia. The Cochrane Library, 2017, 2017, CD012217.	1.5	12



#	ARTICLE	IF	CITATIONS
632	How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2017, 27, 835-844.	0.3	92
633	Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study. <i>Psychopharmacology</i> , 2017, 234, 3-13.	1.5	12
634	Aberrant Cerebellar Connectivity in Bipolar Disorder With Psychosis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017, 2, 438-448.	1.1	35
635	Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. <i>Schizophrenia Research</i> , 2017, 183, 10-21.	1.1	66
636	Video games for schizophrenia. <i>The Cochrane Library</i> , 0, , .	1.5	0
637	Yoga as part of a package of care versus non-standard care for schizophrenia. <i>The Cochrane Library</i> , 2017, , .	1.5	2
638	Haloperidol (route of administration) for people with schizophrenia. <i>The Cochrane Library</i> , 0, , .	1.5	6
639	Chlorpromazine versus lithium for people with schizophrenia. <i>The Cochrane Library</i> , 2017, , .	1.5	0
640	Practice and Learning: Spatiotemporal Differences in Thalamo-Cortical-Cerebellar Networks Engagement across Learning Phases in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2016, 7, 212.	1.3	0
641	Common and distinct structural features of schizophrenia and bipolar disorder: The European Network on Psychosis, Affective disorders and Cognitive Trajectory (ENPACT) study. <i>PLoS ONE</i> , 2017, 12, e0188000.	1.1	74
642	Analysis of EEG entropy during visual evocation of emotion in schizophrenia. <i>Annals of General Psychiatry</i> , 2017, 16, 34.	1.2	36
643	Chlorpromazine versus thiothixene for people with schizophrenia. <i>The Cochrane Library</i> , 0, , .	1.5	1
644	Efficacy of electroconvulsive therapy augmentation for partial response to clozapine: a pilot randomized ECT “sham” controlled trial. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 45-50.	0.6	13
645	Expressive suppression is associated with state paranoia in psychosis: An experience sampling study on the association between adaptive and maladaptive emotion regulation strategies and paranoia. <i>British Journal of Clinical Psychology</i> , 2018, 57, 291-312.	1.7	41
646	Relationship between the duration of methamphetamine use and psychotic symptoms: A two-year prospective cohort study. <i>Drug and Alcohol Dependence</i> , 2018, 187, 363-369.	1.6	33
647	Vesicular monoamine transporter inhibitors versus placebo for antipsychotic-induced tardive dyskinesia. <i>The Cochrane Library</i> , 2018, , .	1.5	2
648	Low serum level of epidermal growth factor in chronic ketamine users. <i>Human Psychopharmacology</i> , 2018, 33, e2656.	0.7	0
649	Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. <i>The Cochrane Library</i> , 2018, 2, CD000459.	1.5	21

#	ARTICLE	IF	CITATIONS
650	Selective noradrenaline reuptake inhibitors for schizophrenia. The Cochrane Library, 2018, 2018, CD010219.	1.5	8
651	Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. The Cochrane Library, 2018, 1, CD000458.	1.5	5
652	Vitamin E for antipsychotic-induced tardive dyskinesia. The Cochrane Library, 2018, 1, CD000209.	1.5	13
653	Benzodiazepines for antipsychotic-induced tardive dyskinesia. The Cochrane Library, 2018, 2018, CD000205.	1.5	12
654	Anticholinergic medication for antipsychotic-induced tardive dyskinesia. The Cochrane Library, 2018, 2018, CD000204.	1.5	24
655	Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. The Cochrane Library, 2018, 2018, CD011057.	1.5	15
656	Clinically significant personality traits in individuals at high risk of developing psychosis. Psychiatry Research, 2018, 261, 498-503.	1.7	14
657	Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). The Cochrane Library, 2018, 2018, CD008074.	1.5	21
658	Early improvement in PANSSâ€³0, PANSSâ€³8, and PANSSâ€³6 scores predicts ultimate response and remission during acute treatment of schizophrenia. Acta Psychiatrica Scandinavica, 2018, 137, 98-108.	2.2	43
659	Calcium channel blockers for antipsychotic-induced tardive dyskinesia. The Cochrane Library, 2018, 2018, CD000206.	1.5	4
660	Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. The Cochrane Library, 2018, 2018, CD000208.	1.5	12
661	Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia. The Cochrane Library, 2018, 4, CD000203.	1.5	8
662	Striatal dopamine release and impaired reinforcement learning in adults with 22q11.2 deletion syndrome. European Neuropsychopharmacology, 2018, 28, 732-742.	0.3	9
663	Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). The Cochrane Library, 2018, 4, CD009412.	1.5	23
664	Exercise as an intervention for firstâ€³episode psychosis: a feasibility study. Microbial Biotechnology, 2018, 12, 307-315.	0.9	91
665	The association of psychopathology with concurrent level of functioning and subjective well-being in persons with schizophrenia spectrum disorders. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 455-459.	1.8	5
666	Minimal Clinically Important Differences (MCID) in Assessing Outcomes of Post-Traumatic Stress Disorder. Psychiatric Quarterly, 2018, 89, 141-155.	1.1	55
667	Overlapping and disease specific trait, response, and reflection impulsivity in adolescents with first-episode schizophrenia spectrum disorders or attention-deficit/hyperactivity disorder. Psychological Medicine, 2018, 48, 604-616.	2.7	14

#	ARTICLE	IF	CITATIONS
668	Serum BDNF Is Positively Associated With Negative Symptoms in Older Adults With Schizophrenia. <i>Biological Research for Nursing</i> , 2018, 20, 63-69.	1.0	15
669	Translating the HAM-D into the MADRS and vice versa with equipercetile linking. <i>Journal of Affective Disorders</i> , 2018, 226, 326-331.	2.0	62
670	Non literal language comprehension in a large sample of first episode psychosis patients in adulthood. <i>Psychiatry Research</i> , 2018, 260, 78-89.	1.7	12
671	Assessing the robustness of direct meta-analysis in the presence of heterogeneity. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 1009-1025.	0.6	2
672	Instrumental Activities of Daily Living Dysfunction among People with Schizophrenia. <i>Indian Journal of Psychological Medicine</i> , 2018, 40, 134-138.	0.6	24
673	Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia. <i>The Cochrane Library</i> , 2018, 2018, CD007964.	1.5	26
674	Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia. <i>The Cochrane Library</i> , 2019, 2019, CD008712.	1.5	36
675	Celecoxib plus standard care for people with schizophrenia. <i>The Cochrane Library</i> , 2018, , .	1.5	0
676	Chlorpromazine versus piperacetazine for schizophrenia. <i>The Cochrane Library</i> , 2018, 10, CD011709.	1.5	8
677	Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia. <i>The Cochrane Library</i> , 2018, 10, CD012398.	1.5	3
678	Saffron (adjunct) for people with schizophrenia who have antipsychotic-induced metabolic syndrome. <i>The Cochrane Library</i> , 0, , .	1.5	3
679	Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms. <i>The Cochrane Library</i> , 0, , .	1.5	1
680	Clozapine versus olanzapine for people with schizophrenia. <i>The Cochrane Library</i> , 2018, , .	1.5	1
681	Clozapine versus quetiapine for people with schizophrenia. <i>The Cochrane Library</i> , 2018, , .	1.5	0
682	Clozapine versus risperidone for people with schizophrenia. <i>The Cochrane Library</i> , 2018, , .	1.5	0
683	Microstructural Findings in White Matter Associated with Cannabis and Alcohol Use in Early-Phase Psychosis: A Diffusion Tensor Imaging and Relaxometry Study. <i>Brain Connectivity</i> , 2018, 8, 567-576.	0.8	3
684	Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis. <i>BMC Psychiatry</i> , 2018, 18, 380.	1.1	23
685	The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. <i>Lancet Psychiatry</i> , the, 2018, 5, 885-894.	3.7	133

#	ARTICLE	IF	CITATIONS
686	Epidemiological Characteristics and Risk Factors of Methamphetamine-Associated Psychotic Symptoms. <i>Frontiers in Psychiatry</i> , 2018, 9, 489.	1.3	15
687	Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis. <i>World Psychiatry</i> , 2018, 17, 316-329.	4.8	119
688	Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 621-623.	1.8	4
689	Suicidality, self-stigma, social anxiety and personality traits in stabilized schizophrenia patients &ndash; a cross-sectional study. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1415-1424.	1.0	17
690	Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study. <i>European Psychiatry</i> , 2018, 53, 58-65.	0.1	16
691	Altered connectivity between striatal and extrastriatal regions in patients with schizophrenia on maintenance antipsychotics: an [ <sup>18</sup> F]fallypride PET and functional MRI study. <i>Synapse</i> , 2018, 72, e22064.	0.6	8
692	Functional remission in schizophrenia: A FROGS-based definition and its convergent validity. <i>Psychiatry Research</i> , 2018, 268, 94-101.	1.7	8
693	Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. <i>Lancet Psychiatry</i> , 2018, 5, 633-643.	3.7	71
694	Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial. <i>European Neuropsychopharmacology</i> , 2018, 28, 1024-1034.	0.3	6
695	Increasing antipsychotic dose for non response in schizophrenia. <i>The Cochrane Library</i> , 2018, 5, CD011883.	1.5	8
696	Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. <i>The Cochrane Library</i> , 2018, 5, CD011884.	1.5	4
697	Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 825-837.	1.0	9
698	Cholinergic medication for antipsychotic-induced tardive dyskinesia. <i>The Cochrane Library</i> , 2018, 3, CD000207.	1.5	21
699	Fluphenazine (oral) versus placebo for schizophrenia. <i>The Cochrane Library</i> , 2020, 2020, CD006352.	1.5	4
700	Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 474-484.	0.7	21
701	Factors associated with poor satisfaction with treatment and trial discontinuation in chronic schizophrenia. <i>CNS Spectrums</i> , 2019, 24, 380-389.	0.7	3
702	Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 985-992.	1.8	39
703	How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2019, 45, 639-646.	2.3	74

#	ARTICLE	IF	CITATIONS
704	Cognitive Analytic Therapy for psychosis: A case series. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , 2019, 92, 359-378.	1.3	10
705	Distinct Differences in Emotional Recognition According to Severity of Psychotic Symptoms in Early-Stage Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019, 10, 564.	1.3	11
706	Perception of social support and psychotic symptoms among persons with schizophrenia: A strategy to lessen caregiver burden. <i>International Journal of Social Psychiatry</i> , 2019, 65, 548-557.	1.6	24
707	Diagnostic stability and long-term symptomatic and functional outcomes in first-episode antipsychotic-naïve patients with schizophrenia. <i>European Psychiatry</i> , 2019, 62, 130-137.	0.1	8
708	Clozapine (generic versus branded) for people with schizophrenia. <i>The Cochrane Library</i> , 2019, , .	1.5	2
709	Olanzapine dose for people with schizophrenia. <i>The Cochrane Library</i> , 0, , .	1.5	2
710	The Feasibility and Efficacy of Social Cognition and Interaction Training for Outpatients With Schizophrenia in Japan: A Multicenter Randomized Clinical Trial. <i>Frontiers in Psychiatry</i> , 2019, 10, 589.	1.3	12
711	Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 205-211.	1.0	15
712	Differential gene expression analysis in blood of first episode psychosis patients. <i>Schizophrenia Research</i> , 2019, 209, 88-97.	1.1	27
713	Association of Choroid Plexus Enlargement With Cognitive, Inflammatory, and Structural Phenotypes Across the Psychosis Spectrum. <i>American Journal of Psychiatry</i> , 2019, 176, 564-572.	4.0	82
714	Visualizing mental representations in schizophrenia patients: A reverse correlation approach. <i>Schizophrenia Research: Cognition</i> , 2019, 17, 100138.	0.7	3
715	Cortical patterning of abnormal morphometric similarity in psychosis is associated with brain expression of schizophrenia-related genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9604-9609.	3.3	200
716	Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients. <i>International Journal of Endocrinology</i> , 2019, 2019, 1-9.	0.6	6
717	Three-Year Follow-Up Study Exploring Metacognition and Function in Individuals With First Episode Psychosis. <i>Frontiers in Psychiatry</i> , 2019, 10, 182.	1.3	9
718	Social Mindfulness and Psychosis: Neural Response to Socially Mindful Behavior in First-Episode Psychosis and Patients at Clinical High-Risk. <i>Frontiers in Human Neuroscience</i> , 2019, 13, 47.	1.0	4
719	Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia. <i>JAMA Psychiatry</i> , 2019, 76, 691.	6.0	18
720	A comparison of the reliability and validity of SF-6D, EQ-5D and HUI3 utility measures in patients with schizophrenia and patients with depression in Singapore. <i>Psychiatry Research</i> , 2019, 274, 400-408.	1.7	27
721	Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 1589-1596.	2.8	26

#	ARTICLE	IF	CITATIONS
722	Abnormal Entropy Modulation of the EEG Signal in Patients With Schizophrenia During the Auditory Paired-Stimulus Paradigm. <i>Frontiers in Neuroinformatics</i> , 2019, 13, 4.	1.3	13
723	The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis. <i>European Psychiatry</i> , 2019, 57, 78-100.	0.1	38
724	Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications. <i>Psychopharmacology</i> , 2019, 236, 1985-1997.	1.5	35
725	Changes in serum TNF- $\alpha$ , IL-18, and IL-6 concentrations in patients with chronic schizophrenia at admission and at discharge. <i>Comprehensive Psychiatry</i> , 2019, 90, 82-87.	1.5	49
726	Clozapine for persistent aggressive behaviour or agitation in people with schizophrenia. <i>The Cochrane Library</i> , 0, , .	1.5	0
727	Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses. <i>The Cochrane Library</i> , 2019, 8, CD006570.	1.5	11
728	Acetylsalicylic acid (aspirin) for schizophrenia. <i>The Cochrane Library</i> , 2019, 2019, CD012116.	1.5	13
729	Interventions for prodromal stage of psychosis. <i>The Cochrane Library</i> , 2019, 2019, .	1.5	43
730	Pharmacological interventions for reduction of weight gain in people with schizophrenia. <i>The Cochrane Library</i> , 2019, , .	1.5	0
731	Electroconvulsive therapy for treatment-resistant schizophrenia. <i>The Cochrane Library</i> , 2019, 2019, CD011847.	1.5	41
732	Peer support for people with schizophrenia or other serious mental illness. <i>The Cochrane Library</i> , 2019, 2019, CD010880.	1.5	49
733	Haloperidol discontinuation for people with schizophrenia. <i>The Cochrane Library</i> , 2019, 4, CD011408.	1.5	8
734	Olanzapine versus placebo for people with schizophrenia. <i>The Cochrane Library</i> , 0, , .	1.5	3
735	Pharmacological interventions for prevention of weight gain in people with schizophrenia. <i>The Cochrane Library</i> , 2019, , .	1.5	0
736	Humour-based interventions for people with schizophrenia. <i>The Cochrane Library</i> , 2019, , .	1.5	1
737	Quetiapine dose for people with schizophrenia. <i>The Cochrane Library</i> , 2019, , .	1.5	3
738	Haloperidol versus olanzapine for people with schizophrenia. <i>The Cochrane Library</i> , 2019, , .	1.5	1
739	Psychosocial interventions for people with both severe mental illness and substance misuse. <i>The Cochrane Library</i> , 2019, 2019, CD001088.	1.5	40

#	ARTICLE	IF	CITATIONS
740	Clinical determinants of social media use in individuals with schizophrenia. PLoS ONE, 2019, 14, e0225370.	1.1	14
741	Efficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2019, 39, 604-610.	0.7	14
742	Transitional discharge interventions for people with serious mental illness. The Cochrane Library, 0, , .	1.5	0
743	Yoga as part of a package of care versus non-standard care for schizophrenia. The Cochrane Library, 2019, 2019, CD012807.	1.5	6
744	Concentrationâ€“Effect Relationships of Psychoactive Drugs and the Problem to Calculate Therapeutic Reference Ranges. Therapeutic Drug Monitoring, 2019, 41, 174-179.	1.0	40
745	Treatments for primary delusional infestation. The Cochrane Library, 2019, 12, CD011326.	1.5	4
746	Modafinil for people with schizophrenia or related disorders. The Cochrane Library, 2019, 12, CD008661.	1.5	3
747	Clinical utility of the Negative Symptom Assessment-16 in individuals with schizophrenia. European Neuropsychopharmacology, 2019, 29, 1433-1441.	0.3	5
748	Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophrenia Research, 2019, 204, 282-288.	1.1	39
749	Glucagonâ€“like peptideâ€“1 receptor agonists for antipsychoticâ€“associated cardioâ€“metabolic risk factors: A systematic review and individual participant data metaâ€“analysis. Diabetes, Obesity and Metabolism, 2019, 21, 293-302.	2.2	69
750	Specific Substantial Dysconnectivity in Schizophrenia: A Transdiagnostic Multimodal Meta-analysis of Resting-State Functional and Structural Magnetic Resonance Imaging Studies. Biological Psychiatry, 2019, 85, 573-583.	0.7	93
752	Testing models of postâ€“traumatic intrusions, traumaâ€“related beliefs, hallucinations, and delusions in a first episode psychosis sample. British Journal of Clinical Psychology, 2019, 58, 154-172.	1.7	21
753	Frontostriatal functional connectivity and striatal dopamine synthesis capacity in schizophrenia in terms of antipsychotic responsiveness: an [ <sup>18</sup> F]DOPA PET and fMRI study. Psychological Medicine, 2019, 49, 2533-2542.	2.7	15
754	Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. European Neuropsychopharmacology, 2019, 29, 127-136.	0.3	39
755	Self-stigma versus stigma resistance in schizophrenia: Associations with resilience, premorbid adjustment, and clinical symptoms. Psychiatry Research, 2019, 271, 396-401.	1.7	27
756	The Psychiatric Phenotype of Anti-NMDA Receptor Encephalitis. Journal of Neuropsychiatry and Clinical Neurosciences, 2019, 31, 70-79.	0.9	40
757	Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology, 2019, 44, 1036-1042.	2.8	116
758	The impact of schizophrenia and intelligence on the relationship between age and brain volume. Schizophrenia Research: Cognition, 2019, 15, 1-6.	0.7	8



#	ARTICLE	IF	CITATIONS
759	Decision-making ability in psychosis: a systematic review and meta-analysis of the magnitude, specificity and correlates of impaired performance on the Iowa and Cambridge Gambling Tasks. <i>Psychological Medicine</i> , 2019, 49, 32-48.	2.7	25
760	The Effect of Reducing the "Jumping to Conclusions" Bias on Treatment Decision-Making Capacity in Psychosis: A Randomized Controlled Trial With Mediation Analysis. <i>Schizophrenia Bulletin</i> , 2019, 45, 784-793.	2.3	6
761	Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 14-32.	1.2	20
762	Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. <i>Molecular Psychiatry</i> , 2019, 24, 1502-1512.	4.1	120
763	The effectiveness of structured exercise programmes on psychological and physiological outcomes for patients with psychotic disorders: A systematic review and meta-analysis. <i>International Journal of Sport and Exercise Psychology</i> , 2020, 18, 336-361.	1.1	8
764	Schizophrenia, cognition, and aging: cognitive deficits and the relationship between test performance and aging. <i>Aging, Neuropsychology, and Cognition</i> , 2020, 27, 40-51.	0.7	2
765	Lower [18F]fallypride binding to dopamine D2/3 receptors in frontal brain areas in adults with 22q11.2 deletion syndrome: a positron emission tomography study. <i>Psychological Medicine</i> , 2020, 50, 799-807.	2.7	2
766	Cognitive and metacognitive factors predict engagement in employment in individuals with first episode psychosis. <i>Schizophrenia Research: Cognition</i> , 2020, 19, 100141.	0.7	7
767	Translating the BDI and BDI-II into the HAMD and vice versa with equipercetile linking. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e24.	1.8	39
768	Developing clinical cut-off scores for the university of California San Diego performance-based skills assessment in patients with schizophrenia. <i>Asian Journal of Psychiatry</i> , 2020, 47, 101844.	0.9	1
769	Cross-Validation of the Arabic Mini International Neuropsychiatric Interview, Module K, for Diagnosis of Schizophrenia and the Arabic Positive and Negative Syndrome Scale. <i>Journal of Psychopathology and Behavioral Assessment</i> , 2020, 42, 139-149.	0.7	1
770	Definitions of relapse in trials comparing antipsychotic maintenance with discontinuation or reduction for schizophrenia spectrum disorders: A systematic review. <i>Schizophrenia Research</i> , 2020, 225, 47-54.	1.1	28
771	Organization framework and preliminary findings from the Athens First-Episode Psychosis Research Study. <i>Microbial Biotechnology</i> , 2020, 14, 343-355.	0.9	10
772	Influences on functional outcome and subjective recovery in individuals with and without First Episode Psychosis: A metacognitive model. <i>Psychiatry Research</i> , 2020, 284, 112643.	1.7	7
773	Cognition and violent behavior in psychotic disorders: A nationwide case-control study. <i>Schizophrenia Research: Cognition</i> , 2020, 19, 100166.	0.7	7
774	Perceptual biases and metacognition and their association with anomalous self experiences in first episode psychosis. <i>Consciousness and Cognition</i> , 2020, 77, 102847.	0.8	14
775	Evidence for preventive treatments in young patients at clinical high risk of psychosis: the need for context. <i>Lancet Psychiatry</i> , 2020, 7, 378-380.	3.7	9
776	Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. <i>Neuropsychopharmacology</i> , 2020, 45, 632-640.	2.8	50



#	ARTICLE	IF	CITATIONS
777	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2020, 34, 3-78.	2.0	259
778	The longitudinal course of schizophrenia: testosterone and progression of the negative symptoms. <i>Nordic Journal of Psychiatry</i> , 2020, 74, 147-154.	0.7	4
779	Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. <i>Neuropsychopharmacology</i> , 2020, 45, 622-631.	2.8	63
780	Quantitative biomarkers to predict response to clozapine treatment using resting EEG data. <i>Schizophrenia Research</i> , 2020, 223, 289-296.	1.1	8
781	Quality of life, symptom severity and level of functioning in people with severe mental illness ready for hospital discharge. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2022, 29, 14-24.	1.2	4
782	Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial. <i>BJPsych Open</i> , 2020, 6, e126.	0.3	3
783	The Effects of Combined Social Cognition and Interaction Training and Paliperidone on Early-Onset Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 525492.	1.3	5
784	Blood-based kynurenine pathway alterations in schizophrenia spectrum disorders: A meta-analysis. <i>Schizophrenia Research</i> , 2020, 223, 43-52.	1.1	20
785	COVID-19 patients managed in psychiatric inpatient settings due to first-episode mental disorders in Wuhan, China: clinical characteristics, treatments, outcomes, and our experiences. <i>Translational Psychiatry</i> , 2020, 10, 337.	2.4	39
786	Premorbid Social Functioning and Affective Symptoms Predict Subjective Outcome Among Outpatients With Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 570857.	1.3	4
787	Aberrant white matter microstructure in treatment-resistant schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2020, 305, 111198.	0.9	4
788	Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design. <i>Schizophrenia Research</i> , 2021, 230, 87-94.	1.1	2
789	Clinical Validity of Subjective Clinical Prognosis in First Episode Psychosis Schizophrenia Patients: An Analysis of Data from the European First Episode Schizophrenia Trial (EUFEST) Study. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 1279-1284.	1.0	0
790	Feasibility and Efficacy of a Psychological Therapy for Patients With a Schizophrenic Psychosis in an Inpatient Setting: Study Protocol of a Randomized Switch Controlled Trial. <i>Frontiers in Public Health</i> , 2020, 8, 391.	1.3	1
791	Maintenance treatment with antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2020, 2020, CD008016.	1.5	56
792	A systematic review of studies with clinician-rated scales on the pharmacological treatment of delusional disorder. <i>International Clinical Psychopharmacology</i> , 2020, 35, 129-136.	0.9	15
793	Heritability of specific cognitive functions and associations with schizophrenia spectrum disorders using CANTAB: a nation-wide twin study. <i>Psychological Medicine</i> , 2022, 52, 1101-1114.	2.7	18
794	Biomarkers for Prediction of Schizophrenia: Insights From Resting-State EEG Microstates. <i>IEEE Access</i> , 2020, 8, 213078-213093.	2.6	20

#	ARTICLE	IF	CITATIONS
795	Problems in measuring the JTC-bias in patients with psychotic disorders with the fish task: a secondary analysis of a baseline assessment of a randomized controlled trial. BMC Psychiatry, 2020, 20, 554.	1.1	11
796	Decreased Plasma Levels of Growth Differentiation Factor 11 in Patients With Schizophrenia: Correlation With Psychopathology and Cognition. Frontiers in Psychiatry, 2020, 11, 555133.	1.3	3
797	Delaying clozapine: how long is too long?. Annals of General Psychiatry, 2020, 33, e100172.	1.1	9
798	Efficacy and Moderators of Cognitive Behavioural Therapy for Psychosis Versus Other Psychological Interventions: An Individual-Participant Data Meta-Analysis. Frontiers in Psychiatry, 2020, 11, 402.	1.3	17
799	Early-Onset Schizophrenia With Predominantly Negative Symptoms: A Case Study of a Drug-Naive Female Patient Treated With Cariprazine. Frontiers in Pharmacology, 2020, 11, 477.	1.6	8
800	Evidence-Based Integrated Intervention in Patients with Schizophrenia: A Pilot Study of Feasibility and Effectiveness in a Real-World Rehabilitation Setting. International Journal of Environmental Research and Public Health, 2020, 17, 3352.	1.2	19
801	Avatar Therapy for people with schizophrenia or related disorders. The Cochrane Library, 2020, 5, CD011898.	1.5	17
802	Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia. JAMA Network Open, 2020, 3, e204693.	2.8	103
803	Computer-based Cognitive Remediation Therapy plus standard care versus standard care for people with schizophrenia or related disorders. The Cochrane Library, 2020, , .	1.5	0
804	Prolonged rather than hasty decision-making in schizophrenia using the box task. Must we rethink the jumping to conclusions account of paranoia?. Schizophrenia Research, 2020, 222, 202-208.	1.1	24
805	Striatal Volume Increase After Six Weeks of Selective Dopamine D2/3 Receptor Blockade in First-Episode, Antipsychotic-Naïve Schizophrenia Patients. Frontiers in Neuroscience, 2020, 14, 484.	1.4	15
806	Are Randomized Controlled Trials on Pharmacotherapy and Psychotherapy for Positive Symptoms of Schizophrenia Comparable? A Systematic Review of Patient and Study Characteristics. Schizophrenia Bulletin, 2020, 46, 496-504.	2.3	11
807	Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12–43 years. Psychological Medicine, 2021, 51, 1570-1580.	2.7	17
808	Identifying Schizophrenia Using Structural MRI With a Deep Learning Algorithm. Frontiers in Psychiatry, 2020, 11, 16.	1.3	78
809	Affective lability across psychosis spectrum disorders. European Psychiatry, 2020, 63, e53.	0.1	17
810	Psychological interventions for psychosis in adolescents. The Cochrane Library, 2020, 7, CD009533.	1.5	8
811	Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: Post-hoc analysis of short- and long-term studies. Journal of Psychopharmacology, 2020, 34, 829-838.	2.0	5
812	Tai Chi plus standard care versus other exercise plus standard care for people with schizophrenia or related disorders. The Cochrane Library, 0, , .	1.5	0

#	ARTICLE	IF	CITATIONS
813	Parenting interventions for people with schizophrenia or related serious mental illness. The Cochrane Library, 2020, , .	1.5	2
814	Family-based interventions versus standard care for people with schizophrenia. The Cochrane Library, 2020, , .	1.5	4
815	A pilot study of biomarkers of oxidative stress in serum and schizophrenia. Psychiatry Research, 2020, 284, 112757.	1.7	15
816	Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study. International Journal of Psychiatry in Clinical Practice, 2020, 24, 10-17.	1.2	2
817	Colour discrimination among patients with schizophrenia in Lebanon. International Journal of Psychiatry in Clinical Practice, 2020, 24, 193-200.	1.2	4
818	Early and very earlyâ€onset schizophrenia compared with adultâ€onset schizophrenia: French FACEâ€SZ database. Brain and Behavior, 2020, 10, e01495.	1.0	38
819	Assessment of Similarity in Antipsychotic Exposureâ€Response Relationships in Clinical Trials Between Adults and Adolescents With Acute Exacerbation of Schizophrenia. Journal of Clinical Pharmacology, 2020, 60, 848-859.	1.0	5
820	Defining cognitive and functional profiles in schizophrenia and affective disorders. BMC Psychiatry, 2020, 20, 39.	1.1	20
821	Predicting factors for non-suicidal self-injury in patients with schizophrenia spectrum disorders and the role of substance use. Asian Journal of Psychiatry, 2020, 52, 102068.	0.9	8
822	Cognitive Impact of Cerebellar Non-invasive Stimulation in a Patient With Schizophrenia. Frontiers in Psychiatry, 2020, 11, 174.	1.3	3
823	A randomized controlled trial of social skills training for patients with treatment-resistant schizophrenia with predominantly negative symptoms. Psychiatry Research, 2020, 287, 112914.	1.7	4
824	Mindfulness Mediates the Effect of a Psychological Online Intervention for Psychosis on Self-Reported Hallucinations: A Secondary Analysis of Voice Hearers From the EviBaS Trial. Frontiers in Psychiatry, 2020, 11, 228.	1.3	6
825	Examination of social decision making in patients with schizophrenia using ultimatum game. Asian Journal of Psychiatry, 2020, 50, 101937.	0.9	7
826	Ketamine increases positive symptoms more than negative and cognitive ones: a systematic review and meta-analysis. Journal of Substance Use, 2021, 26, 1-6.	0.3	1
827	Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 46-52.	0.7	8
828	ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110042.	2.5	9
829	Evaluation of a computer-assisted cognitive remediation program for young people with psychosis: A pilot study. Schizophrenia Research: Cognition, 2021, 23, 100188.	0.7	5
830	Clinically meaningful changes on depressive symptom measures and patientâ€reported outcomes in patients with treatmentâ€resistant depression. Acta Psychiatrica Scandinavica, 2021, 143, 253-263.	2.2	23

#	ARTICLE	IF	CITATIONS
831	Better functional capacity and cognitive performance in clozapine responders compared to non-responders: A cross-sectional study. <i>Schizophrenia Research</i> , 2021, 229, 134-136.	1.1	2
832	Sleep problems and worrying precede psychotic symptoms during an online intervention for psychosis. <i>British Journal of Clinical Psychology</i> , 2021, 60, 48-67.	1.7	6
833	Contrast sensitivity deficits in schizophrenia: A psychophysical investigation. <i>European Journal of Neuroscience</i> , 2021, 53, 1155-1170.	1.2	18
834	Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). <i>Schizophrenia Bulletin</i> , 2021, 47, 505-516.	2.3	51
835	The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18F-DOPA PET and voxel-based morphometry study. <i>Molecular Psychiatry</i> , 2021, 26, 1332-1345.	4.1	23
836	Altered effective connectivity within an oculomotor control network in individuals with schizophrenia. <i>NeuroImage: Clinical</i> , 2021, 31, 102764.	1.4	2
837	Investigating Patient Acceptability of Stratified Medicine for Schizophrenia: A Mixed Methods Study. <i>Schizophrenia Bulletin Open</i> , 2021, 2, sgab016.	0.9	1
838	Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 483-493.	1.5	13
839	Confidence in visual motion discrimination is preserved in individuals with schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2021, 46, E65-E73.	1.4	14
840	Video games for people with schizophrenia. <i>The Cochrane Library</i> , 2021, 2021, CD012844.	1.5	5
841	Effects of aerobic walking on cognitive function in patients with schizophrenia: A randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2021, 134, 173-180.	1.5	10
842	Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: A meta-analysis of randomized controlled trials. <i>Journal of Psychopharmacology</i> , 2021, 35, 221-235.	2.0	21
843	Self-rated health in older adults with schizophrenia: advances and future directions. <i>International Psychogeriatrics</i> , 2021, 33, 105-107.	0.6	0
844	Emerging cycloid psychosis episodes during COVID-19 pandemic: a case series. <i>Nordic Journal of Psychiatry</i> , 2021, 75, 465-471.	0.7	4
845	Characteristics and definitions of ultra-treatment-resistant schizophrenia – A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2021, 228, 218-226.	1.1	28
846	Clozapine-Associated Myocarditis. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 180-185.	0.7	14
847	Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2021, 51, 376-386.	2.7	21
848	Guidelines to understand and compute the number needed to treat. <i>Evidence-Based Mental Health</i> , 2021, 24, 131-136.	2.2	10

#	ARTICLE	IF	CITATIONS
849	How can we estimate QALYs based on PHQ-9 scores? Equipercetile linking analysis of PHQ-9 and EQ-5D. Evidence-Based Mental Health, 2021, 24, 97-101.	2.2	11
850	Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia. BMC Psychiatry, 2021, 21, 164.	1.1	3
851	Research findings on Greek forensic patients found not guilty by reason of insanity. A juxtaposition of patients who committed a criminal offense during their first psychotic episode with those who did so later in the course of their illness. International Journal of Law and Psychiatry, 2021, 75, 101673.	0.5	2
852	Exploring the relationships between illness beliefs and psychosis symptoms among Black African and Caribbean people with non-affective psychosis. Psychosis, 2021, 13, 265-275.	0.4	2
853	Predictors of long-acting injectable antipsychotic treatment discontinuation in outpatients with schizophrenia: relevance of the Drug Attitude Inventory-10. International Clinical Psychopharmacology, 2021, 36, 181-187.	0.9	5
854	Antipsychotic dose reduction compared to dose continuation for people with schizophrenia. The Cochrane Library, 0, , .	1.5	2
855	Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia. The Cochrane Library, 0, , .	1.5	1
856	Analysis of circulating exosomes reveals a peripheral signature of astrocytic pathology in schizophrenia. World Journal of Biological Psychiatry, 2022, 23, 33-45.	1.3	19
857	Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 957-970.	1.0	25
858	Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. Neurology, 2021, 97, e61-e75.	1.5	54
859	Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia. Microbial Biotechnology, 2022, 16, 352-362.	0.9	14
860	Application of machine learning to predict reduction in total PANSS score and enrich enrollment in schizophrenia clinical trials. Clinical and Translational Science, 2021, 14, 1864-1874.	1.5	5
861	Defining negative symptoms remission in schizophrenia using the Brief Negative Symptom Scale. Revista De Psiquiatria Y Salud Mental, 2021, , .	1.0	3
862	Treatment-resistant schizophrenia â€œ A RCT on the effectiveness of repeated-dose sodium nitroprusside. Schizophrenia Research, 2021, 231, 70-72.	1.1	5
863	Self- and caregiver-perceived disability, subjective well-being, quality of life and psychopathology improvement in long-acting antipsychotic treatments: a 2-year follow-up study. International Journal of Psychiatry in Clinical Practice, 2021, 25, 307-315.	1.2	6
864	Potential Link between T102C Polymorphism in the Serotonin Receptors (5-HT2A) Gene and Treatment Response of Risperidone on Schizophrenia. Open Access Macedonian Journal of Medical Sciences, 2021, 9, 288-293.	0.1	0
865	Associations between cognition and white matter microstructure in first-episode antipsychotic-naïve patients with schizophrenia and healthy controls: A multivariate pattern analysis. Cortex, 2021, 139, 282-297.	1.1	5
866	The Effect of Adjunctive Mangosteen Pericarp on Cognition in People With Schizophrenia: Secondary Analysis of a Randomized Controlled Trial. Frontiers in Psychiatry, 2021, 12, 626486.	1.3	3

#	ARTICLE	IF	CITATIONS
867	A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension. Schizophrenia Research, 2021, 232, 45-53.	1.1	25
868	Group Cognitive-Behavioral Therapy via Telebehavioral Health for Those With Psychotic Spectrum Disorders: A Case Series. Cognitive and Behavioral Practice, 2021, 28, 716-729.	0.9	2
869	Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms. Human Psychopharmacology, 2021, 36, e2804.	0.7	5
870	Elevated serum levels of TNF- $\alpha$ , IL-6, and IL-18 in chronic methamphetamine users. Human Psychopharmacology, 2022, 37, e2810.	0.7	9
871	Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia. JAMA Psychiatry, 2021, 78, 848.	6.0	208
872	How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices. Schizophrenia Bulletin, 2022, 48, 27-36.	2.3	7
873	Investigating Predictors of Clozapine Response in Adolescents with Schizophrenia and Schizoaffective Disorder. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 504-510.	0.7	2
874	Effects of Adherence to Pharmacological Treatment on the Recovery of Patients with Schizophrenia. Healthcare (Switzerland), 2021, 9, 1230.	1.0	4
875	Auditory event-related potentials, neurocognition, and global functioning in drug naïve first-episode schizophrenia and bipolar disorder. Psychological Medicine, 2023, 53, 785-794.	2.7	4
876	Unstable Belief Formation and Slowed Decision-making: Evidence That the Jumping-to-Conclusions Bias in Schizophrenia Is Not Linked to Impulsive Decision-making. Schizophrenia Bulletin, 2022, 48, 347-358.	2.3	4
877	Anger Experience and Anger Expression Through Drawing in Schizophrenia: An fNIRS Study. Frontiers in Psychology, 2021, 12, 721148.	1.1	2
878	Exploring the association between social behaviour, trust, and its neural correlates in first episode psychosis patients and in individuals at clinical high risk for psychosis. British Journal of Clinical Psychology, 2022, 61, 629-646.	1.7	3
879	Enhancing stress reactivity and wellbeing in early schizophrenia: A randomized controlled trial of Integrated Coping Awareness Therapy (I-CAT). Schizophrenia Research, 2021, 235, 91-101.	1.1	5
880	The association between chronotype and sleep quality, and cardiometabolic markers in patients with schizophrenia. Chronobiology International, 2022, 39, 77-88.	0.9	7
881	Cognitive function mediates the relationship between visual contrast sensitivity and functional outcome in schizophrenia. Journal of Psychiatric Research, 2021, 144, 138-145.	1.5	2
882	Association between negative symptom domains and happiness in schizophrenia. General Hospital Psychiatry, 2021, 68, 83-89.	1.2	4
883	General physical health advice for people with serious mental illness. , 2011, , CD008567.		12
885	Selective noradrenaline reuptake inhibitors for schizophrenia. The Cochrane Library, 0, , .	1.5	1



#	ARTICLE	IF	CITATIONS
887	Specialised early intervention teams (extended time) for first episode psychosis. The Cochrane Library, 0, , .	1.5	3
888	Specialised early intervention teams for first episode psychosis. The Cochrane Library, 0, , .	1.5	2
890	Impaired meaning-based cognitive skills are specifically associated with poorer subjective quality of life in schizophrenia. Personalized Medicine in Psychiatry, 2020, 23-24, 100062.	0.1	2
891	Associations between P3a and P3b amplitudes and cognition in antipsychotic-naïve first-episode schizophrenia patients. Psychological Medicine, 2019, 49, 868-875.	2.7	18
892	Social motivation in schizophrenia: The impact of oxytocin on vigor in the context of social and nonsocial reinforcement.. Journal of Abnormal Psychology, 2018, 127, 116-128.	2.0	20
894	Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials. BMJ Open, 2014, 4, e005708.	0.8	8
895	Assessing Long-Term Test-Retest Reliability of the CPT-IP in Schizophrenia. PLoS ONE, 2014, 9, e84780.	1.1	4
896	Longitudinal Changes in Total Brain Volume in Schizophrenia: Relation to Symptom Severity, Cognition and Antipsychotic Medication. PLoS ONE, 2014, 9, e101689.	1.1	92
897	Follow up of the Impact of Family-Centered Psychoeducation Based on Atkinson and Coia's Model on the Relapse and Severity of Symptoms in Schizophrenia. Iranina Journal of Psychiatric Nursing, 2017, 5, 27-33.	0.2	2
898	The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia. Dialogues in Clinical Neuroscience, 2018, 20, 215-221.	1.8	12
899	Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-66.	0.9	2
900	A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technology Assessment, 2014, 18, vii-viii, xiii-xxv, 1-188.	1.3	179
901	Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT. Health Technology Assessment, 2019, 23, 1-144.	1.3	16
902	A contingency management intervention to reduce cannabis use and time to relapse in early psychosis: the CIRCLE RCT. Health Technology Assessment, 2019, 23, 1-108.	1.3	16
903	Depressive Symptomatology and Attributional Style in Patients with Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2009, 3, 31-38.	1.4	5
904	Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Journal of Clinical Psychiatry, 2012, 73, 526-532.	1.1	78
905	Long-Acting Injectable Antipsychotics: An Underutilized Treatment Option. Journal of Clinical Psychiatry, 2014, 75, 1263-1265.	1.1	21
906	Gender Differences in Serum Prolactin Levels in Drug Naïve First Episode Schizophrenia. Open Journal of Psychiatry, 2015, 05, 165-169.	0.2	1

#	ARTICLE	IF	CITATIONS
907	Excessive Daytime Sleepiness in Schizophrenia: A Naturalistic Clinical Study. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, VC06-VC08.	0.8	10
908	Olanzapine and Olanzapine Pamoate. , 2021, , 296-317.		0
909	What Is an Adequate Antipsychotic Trial? Using Plasma Levels to Optimize Psychiatric Response and Tolerability. , 2021, , 114-146.		0
910	Parenting interventions for people with schizophrenia or related serious mental illness. The Cochrane Library, 2021, 2021, CD013536.	1.5	4
911	Humour-based interventions for people with schizophrenia. The Cochrane Library, 2021, 2021, CD013367.	1.5	1
912	Discontinuation and remission rates and social functioning in patients with schizophrenia receiving secondâ€­generation antipsychotics: 52â€­week evaluation of <scp>JUMPs</scp>, a randomized, openâ€­label study. Psychiatry and Clinical Neurosciences, 2022, 76, 22-31.	1.0	4
913	Oxidative stress-mediated particulate matter affects the risk of relapse in schizophrenia patients: Air purification intervention-based panel study. Environmental Pollution, 2022, 292, 118348.	3.7	7
914	Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry,the, 2021, 8, 969-980.	3.7	114
915	Satisfaction with social connectedness as a predictor for positive and negative symptoms of psychosis: A PHAMOUS study. Schizophrenia Research, 2021, 238, 121-127.	1.1	2
916	Kapitel 8 Literaturverzeichnis. , 2007, , 167-196.		0
919	Screening programmes for helping mental health professionals to detect violent victimisation in people with severe mental illness. The Cochrane Library, 0, , .	1.5	0
920	Early Antipsychotic Response Predictors in Schizophrenia: A Naturalistic Study. Journal of Psychology & Clinical Psychiatry, 2014, 1, .	0.0	0
921	Standardisierte Befunddiagnostik in der Psychiatrie. , 2015, , 1-25.		0
922	Standardisierte Befunddiagnostik in der Psychiatrie. , 2017, , 577-600.		0
923	Brexiprazole versus placebo for people with schizophrenia. The Cochrane Library, 0, , .	1.5	1
924	ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN RISPERIDONE KOMBINASI DAN HALOPERIDOL KOMBINASI PADA PASIEN SKIZOFRENIA DI RSJ. DR. V. L. RATUMBUYSANG PROVINSI SULAWESI UTARA. Majalah Farmasi Dan Farmakologi, 2019, 22, 69-72.	0.1	0
925	Bipolar bozukluk ve Å“izofrenide anksiyete duyarlıÄ±Ä±Ä±. Cukurova Medical Journal, 2020, 45, 721-730.	0.1	0
926	Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment. Consortium Psychiatricum, 2020, 1, 43-51.	0.2	1



#	ARTICLE	IF	CITATIONS
928	Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 736822.	1.3	1
929	Psychosocial Effects of the COVID-19 Pandemic on Patients With Schizophrenia and Their Caregivers. <i>Frontiers in Psychology</i> , 2021, 12, 729793.	1.1	13
930	The "delayed onset" of antipsychotic action—an idea whose time has come and gone. <i>Journal of Psychiatry and Neuroscience</i> , 2006, 31, 93-100.	1.4	84
931	Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale. <i>Innovations in Clinical Neuroscience</i> , 2012, 9, 15-24.	0.1	11
932	Combination and high-dose atypical antipsychotic therapy in patients with schizophrenia: systematic review. <i>CADTH Technology Overviews</i> , 2012, 2, e2301.	0.5	9
933	Rating Scales and Safety Measurements in Bipolar Disorder and Schizophrenia -. <i>Psychopharmacology Bulletin</i> , 2017, 47, 77-109.	0.0	2
934	Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future Directions. <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 77-81.	0.1	30
935	Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia. <i>Shanghai Archives of Psychiatry</i> , 2018, 30, 178-187.	0.7	3
936	Magnetic Seizure Therapy Compared to Electroconvulsive Therapy for Schizophrenia: A Randomized Controlled Trial. <i>Frontiers in Psychiatry</i> , 2021, 12, 770647.	1.3	5
937	Feasibility of an Intervention Delivered via Mobile Phone and Internet to Improve the Continuity of Care in Schizophrenia: A Randomized Controlled Pilot Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12391.	1.2	6
938	The role of white matter abnormality in the left anterior corona radiata: In relation to formal thought disorder in patients with schizophrenia. <i>Psychiatry Research</i> , 2022, 307, 114302.	1.7	3
939	Clinical correlation but no elevation of striatal dopamine synthesis capacity in two independent cohorts of medication-free individuals with schizophrenia. <i>Molecular Psychiatry</i> , 2022, 27, 1241-1247.	4.1	7
940	Early Antipsychotic Nonresponse as a Predictor of Nonresponse and Nonremission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2022, , .	0.3	7
941	Hippocampal Subfield Volumes and Cognitive Function in Schizophrenia and Mood Disorders. <i>Neuropsychobiology</i> , 2022, 81, 204-214.	0.9	6
942	ENHANCE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin for Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	0.9	4
943	The short and long-term effects of aerobic, strength, or mixed exercise programs on schizophrenia symptomatology. <i>Scientific Reports</i> , 2021, 11, 24300.	1.6	4
944	Defining negative symptoms remission in schizophrenia using the Brief Negative Symptom Scale. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2022, 15, 3-13.	0.2	1
945	Dynamic Functional Thalamocortical Dysconnectivity in Schizophrenia Predicts Antipsychotics Response. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
946	Altered glutamate level and its association with working memory among patients with treatment-resistant schizophrenia (TRS): a proton magnetic resonance spectroscopy study. <i>Psychological Medicine</i> , 2023, 53, 3220-3227.	2.7	3
947	Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness. <i>World Journal of Psychiatry</i> , 2022, 12, 521-532.	1.3	1
948	A systematic review of social functioning outcome measures in schizophrenia with a focus on suitability for intervention research. <i>Schizophrenia Research</i> , 2022, 241, 275-291.	1.1	10
949	The neurobiological characterization of distinct cognitive subtypes in early-phase schizophrenia-spectrum disorders. <i>Schizophrenia Research</i> , 2022, 241, 228-237.	1.1	6
950	Efficacy of metacognitive training on symptom severity, neurocognition and social cognition in patients with schizophrenia: A <scp>single-blind</scp> randomized controlled trial. <i>Scandinavian Journal of Psychology</i> , 2022, , .	0.8	5
951	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. <i>Lancet Psychiatry</i> , 2022, 9, 291-306.	3.7	6
952	Pragmatic implementation of the Clinical Global Impression Scale of Severity as a tool for measurement-based care in a first-episode psychosis program. <i>Schizophrenia Research</i> , 2022, 243, 147-153.	1.1	3
953	Decisional capacity in young people with first episode psychosis, major depressive disorder and no mental disorder. <i>Schizophrenia Research: Cognition</i> , 2022, 28, 100228.	0.7	2
954	Measurement Based Care in a first episode psychosis program: Development of an algorithm of care based on the Clinical Global Impressions Scale. <i>Journal of Psychiatric Research</i> , 2022, 150, 8-16.	1.5	1
955	Effect of Vitamin D Supplementation on Outcomes in People With Early Psychosis. <i>JAMA Network Open</i> , 2021, 4, e2140858.	2.8	14
956	The Effectiveness of Chlorpromazine to Decrease the Level of Tumor Necrosis Factor-Alpha Serum in Schizophrenic Patients with Coronavirus Disease 2019. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2021, 9, 1606-1616.	0.1	0
957	Benefits of Social Contact in Individuals With Psychotic Symptoms: Do Closeness of the Contact and Empathic Skills Make the Difference?. <i>Frontiers in Psychology</i> , 2021, 12, 769091.	1.1	4
958	Elevated Serum Purine Levels in Schizophrenia: A Reverse Translational Study to Identify Novel Inflammatory Biomarkers. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 645-659.	1.0	4
959	Scalability of the Positive and Negative Syndrome Scale in first-episode schizophrenia assessed by Rasch models. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 21-35.	2.2	4
960	Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotics as a Predictor of Relapse in Schizophrenia Spectrum Disorders: A 1-Year Pilot Study. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 805-810.	1.0	5
976	What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial. <i>Frontiers in Psychiatry</i> , 2022, 13, 816339.	1.3	4
977	Cognitive behavioural therapy plus standard care for first episode psychosis. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	1
978	Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. <i>World Psychiatry</i> , 2022, 21, 295-307.	4.8	44

#	ARTICLE	IF	CITATIONS
979	Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. <i>Health Technology Assessment</i> , 2022, 26, 1-174.	1.3	16
980	Machine Learning Algorithm-Based Prediction Model for the Augmented Use of Clozapine with Electroconvulsive Therapy in Patients with Schizophrenia. <i>Journal of Personalized Medicine</i> , 2022, 12, 969.	1.1	3
981	Psychoeducation for the parents of people with severe mental illness. <i>The Cochrane Library</i> , 2022, .	1.5	0
982	Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial. <i>Schizophrenia Research</i> , 2022, 246, 49-59.	1.1	1
983	Assessing coherence through linguistic connectives: Analysis of speech in patients with schizophrenia-spectrum disorders. <i>Schizophrenia Research</i> , 2023, 259, 48-58.	1.1	3
984	A study of emotional intelligence in an Egyptian sample of offspring of patients with schizophrenia. <i>Middle East Current Psychiatry</i> , 2022, 29, .	0.5	0
985	Latent Profiles of Premorbid Adjustment in Schizophrenia and Their Correlation with Measures of Recovery. <i>Journal of Clinical Medicine</i> , 2022, 11, 3840.	1.0	3
986	Cognitive behavioural therapy without medication for schizophrenia. <i>The Cochrane Library</i> , 2022, .	1.5	1
987	Cognitive behavioural therapy (group) for schizophrenia. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	3
988	Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	3
989	Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2022, 48, 1273-1283.	2.3	5
990	Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia. <i>Patient Preference and Adherence</i> , 0, Volume 16, 1805-1817.	0.8	4
991	Healthcare Provider Engagement with a Novel Dashboard for Tracking Medication Ingestion: Impact on Treatment Decisions and Clinical Assessments for Adults with Schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 18, 1521-1534.	1.0	2
992	Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022, 20, 567-572.	0.9	3
993	The Ketogenic Diet for Refractory Mental Illness: A Retrospective Analysis of 31 Inpatients. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	28
994	Linkage of Young Mania Rating Scale to Clinical Global Impression Scale to Enhance Utility in Clinical Practice and Research Trials. <i>Pharmacopsychiatry</i> , 2023, 56, 18-24.	1.7	5
995	Mindfulness-based interventions for non-affective psychosis: a comprehensive systematic review and meta-analysis. <i>Annals of Medicine</i> , 2022, 54, 2339-2352.	1.5	8
996	Reduced cortical cerebral blood flow in antipsychotic-free first-episode psychosis and relationship to treatment response. <i>Psychological Medicine</i> , 2023, 53, 5235-5245.	2.7	7

#	ARTICLE	IF	CITATIONS
997	Behavioural family interventions versus structural family interventions for people with schizophrenia. The Cochrane Library, 2022, 2022, .	1.5	0
998	High-intensity interval training may reduce depressive symptoms in individuals with schizophrenia, putatively through improved VO2max: A randomized controlled trial. Frontiers in Psychiatry, 0, 13, .	1.3	10
999	Symptom monitoring based on digital data collection during inpatient treatment of schizophrenia spectrum disorders – A feasibility study. Psychiatry Research, 2022, 316, 114773.	1.7	1
1000	Undiagnosed Psychotic Disorder in Autistic Individuals with Intellectual Disabilities and Suspected Obsessive-Compulsive Disorder: An Explorative, Clinical Study. Journal of Mental Health Research in Intellectual Disabilities, 2023, 16, 226-252.	1.3	8
1001	The Influence of Trial-By-Trial Feedback on Trust in Health, First-Episode and Chronic Psychosis. Games, 2022, 13, 59.	0.4	1
1002	Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia. The Cochrane Library, 2022, 2022, .	1.5	2
1003	Modeling Approach with Therapeutic Drug Monitoring Data to Describe Time Course of Clozapine Exposure and PANSS Scores. Therapeutic Drug Monitoring, 2022, Publish Ahead of Print, .	1.0	0
1004	Positive and negative syndrome scale in forensic patients with schizophrenia spectrum disorders: a systematic review and meta-analysis. Annals of General Psychiatry, 2022, 21, .	1.2	2
1005	Pharmacological interventions for prevention of weight gain in people with schizophrenia. The Cochrane Library, 2023, 2023, .	1.5	7
1006	Altered Patterns of Brain Glucose Metabolism Involve More Extensive and Discrete Cortical Areas in Treatment-resistant Schizophrenia Patients Compared to Responder Patients and Controls: Results From a Head-to-Head 2-[18F]-FDG-PET Study. Schizophrenia Bulletin, 2023, 49, 474-485.	2.3	5
1007	Associations of the serum kynurenine pathway metabolites with P50 auditory gating in non-smoking patients with first-episode schizophrenia. Frontiers in Psychiatry, 0, 13, .	1.3	0
1008	Disrupted local functional connectivity in schizophrenia: An updated and extended meta-analysis. , 2022, 8, .		8
1009	Social affective forecasting and social anhedonia in schizophrenia-spectrum disorders: a daily diary study. , 2022, 8, .		2
1010	Identifying psychiatric manifestations in schizophrenia and depression from audio-visual behavioural indicators through a machine-learning approach. , 2022, 8, .		2
1011	Predictors of Internalized Stigma in Patients with Schizophrenia in Northern Chile: A Longitudinal Study. Healthcare (Switzerland), 2022, 10, 2269.	1.0	0
1012	Cannabidiol for people with schizophrenia. The Cochrane Library, 2022, 2022, .	1.5	0
1013	The use of integrated behavioural z-scoring in behavioural neuroscience – A perspective article. Journal of Neuroscience Methods, 2023, 384, 109751.	1.3	2
1014	Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial. Current Neuropharmacology, 2023, 21, 424-436.	1.4	0

#	ARTICLE	IF	CITATIONS
1015	Computerized cognitive and social cognition training in schizophrenia for impulsive aggression. Schizophrenia Research, 2023, 256, 117-125.	1.1	1
1016	Antipsychotic dose reduction compared to dose continuation for people with schizophrenia. The Cochrane Library, 2022, 2022, .	1.5	6
1017	Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study. BMJ Open, 2022, 12, e062570.	0.8	1
1018	Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: Two open-label pilot studies on treatment-resistant patients. Journal of Psychiatric Research, 2023, 158, 319-329.	1.5	5
1019	Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD. International Journal of Neuropsychopharmacology, 2023, 26, 198-206.	1.0	3
1020	Empathic Accuracy Task: Indian Adaptation and Validation. Indian Journal of Psychological Medicine, 0, , 025371762211415.	0.6	0
1021	Placebo versus no treatment for people with schizophrenia. The Cochrane Library, 2023, 2023, .	1.5	0
1022	Effect of antipsychotic use by patients with schizophrenia on deceleration capacity and its relation to the corrected QT interval. General Hospital Psychiatry, 2023, 81, 15-21.	1.2	0
1023	A fine-grained analysis of the jumping-to-conclusions bias in schizophrenia: Data-gathering, response confidence, and information integration. Judgment and Decision Making, 2009, 4, 587-600.	0.8	18
1024	Frequency-domain analysis of transient visual evoked potentials in schizophrenia. Documenta Ophthalmologica, 0, , .	1.0	0
1025	Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). Lancet Psychiatry,the, 2023, 10, 197-208.	3.7	14
1026	Aripiprazole versus brexpiprazole for people with schizophrenia. The Cochrane Library, 2023, 2023, .	1.5	0
1027	Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials. BMJ Open, 2023, 13, e064504.	0.8	0
1028	Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology, 2023, 43, 97-105.	0.7	1
1029	Does occupational status predict symptomatic remission in outpatients with schizophrenia treated with long-acting antipsychotics? A 6-month follow-up study. Minerva Psychiatry, 0, , .	0.3	0
1030	Meta-cognitive training for schizophrenia. The Cochrane Library, 2023, 2023, .	1.5	0
1031	Intra and inter-individual variability in functional connectomes of patients with First Episode of Psychosis. Neurolmage: Clinical, 2023, 38, 103391.	1.4	1
1032	Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety. Neuropsychiatric Disease and Treatment, 0, Volume 19, 749-757.	1.0	2

#	ARTICLE	IF	CITATIONS
1033	Associations of internalized stigma with psychosocial functioning and quality of life in people with schizophrenia. International Journal of Social Psychiatry, 0, , 002076402311640.	1.6	0
1034	Influences of race and clinical variables on psychiatric genetic research participation: Results from a schizophrenia sample. PLoS ONE, 2023, 18, e0284356.	1.1	2
1035	Post-incident debriefing for people with schizophrenia after coercive measures. The Cochrane Library, 2023, 2023, .	1.5	1
1036	Mismatch negativity predicts initial auditory-based targeted cognitive training performance in a heterogeneous population across psychiatric disorders. Psychiatry Research, 2023, 327, 115215.	1.7	0
1037	Abnormalities of Regional Brain Activity in Patients With Schizophrenia: A Longitudinal Resting-State fMRI Study. Schizophrenia Bulletin, 2023, 49, 1336-1344.	2.3	2
1045	Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review and Meta-Analysis of Evidence-Based Management Options. CNS Drugs, 2023, 37, 499-512.	2.7	2